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CHAPTER-I 
INTRODUCTION 
For many decades treatment of an acute disease (or) a chronic illness has been mostly 
accomplished by delivery of drugs to patients using various pharmaceutical conventional 
dosage forms (such as tablets, capsules, pills, suppositories, creams, ointments, liquids, 
aerosols and injectables as drug carriers) (Chien Yie.W, 2005).  Even today conventional 
drug delivery system occupies most of the part in a prescription as well as drug store. This 
type of drug delivery system is known to provide a prompt release of drug.  Therefore, to 
achieve as well as to maintain the drug concentration within the therapeutically effective 
range needed for treatment, it is often necessary to take this type of drug delivery system 
several times a day (Chien Yie.W, 2005). This results in significant fluctuations in drug 
release. 
 
 
FIGURE 1 
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DISADVANTAGES OF CONVENTIONAL DOSAGE FORM  
Poor patient compliance - increased chances of missing the dose of a drug with short half 
life for which frequent administration is necessary (Brahmankar D.M and Sunil B.Jaiswal, 
2009). 
A typical peak-valley plasma concentration-time profile is obtained which makes 
attainment of steady state condition is difficult. 
The unavoidable fluctuations in the drug concentration may lead to under-medication or  
over-medication  as the Css values fall or rise beyond the therapeutic range  
The fluctuating drug levels may lead to precipitation of adverse effects especially of a 
drug with small therapeutic index whenever over-medication. 
 To overcome the above disadvantages, development of drug delivery systems capable 
of controlling the rate of drug delivery, sustaining the duration of therapeutic action and/or 
targeting the delivery of drug to a particular tissue (Chien Yie.W, 2005)
.
 
They are as follows (Aulton.M.E, 2002). 
1. Delayed release. 
2. Repeat action. 
3. Prolonged release. 
4. Sustained Release. 
5. Extended release. 
6. Controlled Release (Rate controlled). 
7. Modified release. 
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1) Delayed Release  
Delayed Release indicates the drug is not being released immediately following 
administration but at later time. Ex: enteric coated tablets; pulsatile release capsules. 
2) Repeat action 
Repeat action indicates that an indivual dose is released fairly soon after 
administration and second or third doses are subsequently at intermittent intervals. 
3) Prolonged release 
Prolonged release indicates that the drug is provided for absorption over a longer 
period of time than from a conventional dosage form. However there is an implication that 
onset is delayed because of an overall slower release rate from the dosage form. 
4) Sustained Release  
 Sustained Release indicates an initial release of drug sufficient to provide a 
therapeutic dose soon after administration and then a gradual release over the extended 
period. 
5) Extended Release  
 Sustained release dosage forms release drug slowly, so that plasma concentrations are 
maintained at a therapeutic level for a prolonged period of time. (Usually between 8 and 12 
hours)  
6) Controlled Release 
Controlled release dosage forms release the drug at a constant rate, which is 
predictable and also the release rate is reproducible from one unit to another. It provides 
plasma concentrations that remain invariant with time. 
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7) Modified Release 
 Modified Release dosage forms are defined by the USP as those whose drug release 
characteristics of time course and for location are chosen to accomplish therapeutic or 
convenience objectives not offered by conventional forms whereas an extended release 
dosage form allows a 2 fold reduction in dosing frequency or increase in patient compliance 
or therapeutic performance. It is interesting to note that the USP considers that the terms 
controlled release prolonged release and sustained release are interchangeable with extended 
release.  
CLASSIFICATION OF CONTROLLED DRUG DELIVERY SYSTEMS (DDS) 
(Brahmankar D.M and Sunil B.Jaiswal, 2009).
 
 
1. Rate-preprogrammed drug delivery systems.  
2. Activation-modulated drug delivery systems. 
3. Feedback-regulated drug delivery systems.  
4. Site-targeting drug delivery systems. 
TARGETED or SITE-SPECIFIC DDS: 
 Targeted DDS refers to systems that place the drug at or near the receptor site or site 
of action.  Targeted drug delivery implies selective and effective localization of drug into the 
target(s) at therapeutic concentrations with limited access to target sites (Remington, 2002).  
 A targeted drug delivery system is preferred in the following situations: 
Pharmaceutical: drug instability, low solubility. 
Pharmacokinetic: short half-life, large volume of distribution, poor absorption. 
Pharmacodynamic: low solubility, low therapeutic index. 
 Targeted drug delivery may provide maximum therapeutic activity by preventing drug 
degradation or inactivation during transit to the target sites. Meanwhile, it can protect the 
body from the adverse effects because of inappropriate disposition, and minimize toxicity of 
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potent drugs by reducing dose. An ideal targeted delivery system should be nontoxic, 
biocompatible, biodegradable and physic chemically stable in vivo and in vitro. The 
preparation of the delivery system must be reasonably simple, reproducible and                 
cost-effective. 
Site-targeted DDSs have also been characterized as 
• Passive targeting: refers to natural or passive disposition of a drug-carrier based on 
the physiochemical characteristics of the system in relation to the body. 
• Active targeting: refers to alteration of the natural disposition of the drug carrier, 
directing it to specific cells, tissues or organs; for e.g. use of legends or monoclonal 
antibodies which can target specific sites. 
• Inverse targeting 
• Legend mediated targeting 
• Physical targeting (Triggered release) 
• Dual targeting 
• Double targeting 
• Combination targeting (Vyas S.P.and Khar R.K, 2002). 
 Site-targeted DDS can be classified into three broad categories 
First-order targeting: refers to DDS that delivers the drug to the capillary bed or the 
active site. 
Second-order targeting: refers to DDS that delivers the drug to a specific cell type 
such as the tumor cells and not to the normal cells. 
Third-order targeting: refers to DDS that delivers the drug intracellular. 
Drug targeting often requires carriers for selective delivery and can serve following 
purposes- 
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• Protect the drug from degradation after administration. 
• Improve transport or delivery of drug to cells. 
• Decrease clearance of drug. 
Combination of the above Carriers for drug targeting are of two types- 
• Carriers covalently bonded to drug: where the drug release is required for 
pharmacological activity. 
• Carriers not covalently bonded to drug: where simple uncoating of the drug is 
required for pharmacological activity. E.g. liposomes. 
The various carriers used for drug targeting are- 
• Polymeric carriers, 
• Albumin, 
• Lipoproteins,   
• Liposomes,  
• Niosomes, 
• Microspheres, 
• Nanoparticles, 
• Antibodies, 
• Cellular carriers and  
• Macromolecules. 
COLLOIDAL DRUG CARRIERS: (Vyas S.P and Roop K.Khar, 2008). 
 Colloidal drug delivery systems include micro- and Nanoparticles, macromolecular 
complexes (e.g. lipoproteins), liposomes and niosomes. In many cases, colloidal carriers are 
used to improve stability of the drug either in biological fluids or in the formulation, to 
develop extended-release systems with targeting features and/or to enhance the therapeutic 
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efficacy and reduce drug toxicity by modifying the distribution and controlling the 
disposition of the drug 
 
(Aulton .M.E). 
ADVANTAGES OF CONTROLLED DRUG DELIVERY SYSTEM (Jain N.K.2006). 
• Employ less total drug, optimize therapy and improved patient compliance, 
• Minimize (or) eliminate local side effects and drug accumulation with chronic 
dosing,  
• Obtain less potential or reduction in drug activity with chronic use, 
• Improve control of condition i.e.; reduce fluctuation in drug level, improve 
bioavailability and treatment efficiencies of some drugs, 
• Make use of specific drugs e.g.; sustained release aspirin for morning relief of 
arthritis by dosing earlier,  
• Maintenance of optimum therapeutic drug concentration in the blood with 
minimum fluctuations,  
• Predictable and reproducible release rates for extended duration, 
• Enhancement of activity duration for short half life drug,  
• Elimination of frequent dosing, wastage of drug and inconvenience of night time 
administration of drug. 
• Reduction of the incidence, degree of toxicity, side effects and irritation of GI 
tract caused by some orally administered drugs. 
DISADVANTAGES OF CONTROLLED DRUG DELIVERY SYSTEM  
• High cost. 
• Unpredictable (or) poor in-vitro – in-vivo correlation. 
• Dose dumping. 
• Reduce potential for dosage adjustment. 
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• Increases first pass clearance. 
• Poor systemic availability in general (Vyas S.P.and Khar R.K, 2002). 
FACTORS INFLUENCING THE DESIGN AND PERFORMANCE OF 
CONTROLLED DRUG DELIVERY SYSTEMS  
1) Drug Properties / Physiochemical Properties  
- Partition co-efficient.  
- Drug Stability. 
- Protein binding. 
- Molecular size and diffusivity. 
- Aqueous solubility (Vyas S.P.and Khar R.K, 2002) (Jain.N.K, 2006). 
2) Biological Properties  
- Absorption. 
- Distribution.  
- Metabolism. 
- Elimination and biological half-life. 
- Dose size. 
- Route of drug delivery. 
- Target sites. 
- Acute or chronic therapy. 
- The pathological disease. 
- The patient condition. 
- Duration of action. 
- Margin of safety. 
- Circadian rhythm. 
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3) Physiological Properties  
- Prolonged drug absorption. 
- Variability in GI Emptying and motility. 
- Gastro Intestinal Blood flow. 
4) Pharmacokinetic Properties  
- Dose dumping.  
- First Pass metabolism. 
- Variability of urinary pH effect on drug elimination. 
- Enzyme induction/inhibition upon multiple dosing. 
5) Pharmacological properties  
- Changes in drug effect upon multiple dosing. 
- Sensitizing / tolerance. 
DRUGS UNSUITABLE FOR CONTROLLED DRUG DELIVERY  
1. Short / long elimination half life. 
2. Narrow therapeutic index. 
3. Poor absorption. 
4. Active absorption.  
5. Large doses. 
6. Low aqueous s solubility. 
7. Extensive first pass metabolism (Vyas S.P.and Khar R.K, 2002). 
FUTURE TRENDS IN CONTROLLED DRUG DELIVERY SYSTEM                       
 The most exciting and challenging opportunities in controlled drug delivery lie in the 
arena of responsive delivery system, with which it will be possible to deliver drug through 
implantable devices in response to a measured blood level and to deliver the drug precisely to 
a target size (Vyas S.P.and Khar R.K, 2002). 
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CHAPTER-II 
VESICULAR SYSTEM-REVIEW 
The vesicular systems are highly ordered assemblies of one or several concentric lipid 
bilayer formed, when certain ampiphilic building blocks are confronted with water. Vesicles can 
be formed from a diverse range of ampiphilic building blocks. Biologic origin of these vesicles 
was first reported in 1965 by Bingham, and was given the name Bingham bodies. Drug Carrier 
can be engineered to slowly degrade, react to stimuli and be site-specific. The ultimate Aim is to 
control degradation of drug and loss, prevention of harmful side effects and increase the 
Availability of the drug at the disease site. Encapsulation of a drug in vesicular structures can be 
predicted to prolong the existence of the drug in systemic circulation, and perhaps, reduces The 
toxicity if selective uptake can be achieved .Lipid vesicles are one type of many Experimental 
models of biomembranes which evolved successfully, as vehicles for controlled delivery. For the 
treatment of intracellular infections, conventional chemotherapy is not effective, due to limited 
permeation of drugs into cells. This can overcome by the use of Vesicular drug delivery systems. 
Vesicular drug delivery system has some of the advantages like (Amit Kumar Jha et al., 2011). 
Prolong the existence of the drug in systemic circulation, and perhaps, reduces the 
toxicity if selective uptake can be achieved due to the delivery of drug directly to the site of 
infection. 
Improves the bioavailability especially in the case of poorly soluble drugs. 
Both hydrophilic and lipophilic drugs can be incorporated. 
Delays elimination of rapidly metabolizable drugs and thus function as sustained release 
systems. 
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These vesicular systems are accompanied with some problems like drug carriers and 
externally triggered (e.g., temperature, pH, or magnetic sensitive) carriers load drugs passively, 
which may lead to low drug loading efficiency and drug leakage in preparation, preservation and 
transport in vivo. 
Liposomes: 
The liposomes have emerged as most practically useful carriers for in-vivo drug delivery 
as majority of reports has concentrated on the use of phospholipids vesicles or liposomes as 
potential drug carrier systems. Liposomes or lipid based vesicles are microscopic (unilamellar 
ormultilamellar) vesicles that are formed as a result of self-assembly of phospholipids in an 
aqueous media resulting in closed bilayer structures. The assembly into closed bilayer structures 
is a spontaneous process and usually needs some input of energy in the form of physical 
agitation, sonication, heat etc. Since lipid bilayer membrane encloses an aqueous core, both 
water and lipid soluble drugs can be successfully entrapped into the liposomes. The lipid soluble 
or lipophilic drugs get entrapped within the bilayer membrane whereas water soluble or 
hydrophilic drugs get entrapped in the central aqueous core of the vesicles .Liposomes are 
potential carrier for controlled drug release of tumors therapeutic agents and antibiotic, for gene 
and antisense therapy through nucleic acid sequence delivery, immunization through antigen 
delivery and for anti-Parkinson’s. In last one decade, pharmaceutical researchers use the tools of 
biophysics in evaluating liposomal dosage forms. Liposomes have covered predominantly 
medical, albeit some non-medical areas like bioreactors, catalysts, cosmetics and ecology. 
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Advantage: 
• Liposomes supply both a lipophilic environment and aqueous “milieu interne” in one 
system and are therefore suitable for delivery of hydrophobic, amphipathic and 
hydrophilic drugs and agents. 
• Liposomes could encapsulate not only small molecules but also macromolecules like 
superoxide dismutase, hemoglobin, erythropoietin, interleukin-2 and interferon-g. 
• Liposomes reduced toxicity and increased stability of entrapped drug via encapsulation 
• (Eg.Amphotericin B, Taxol). 
• Liposomes help to reduce exposure of sensitive tissues to toxic drugs. 
• Alter the pharmacokinetic and pharmacodynamic property of drugs (reduced elimination, 
• Increased circulation life time). 
Limitation: 
• High production cost 
• Leakage and fusion of encapsulated drug / molecules. 
• Sometimes phospholipids undergoes oxidation and hydrolysis 
• Short half-life 
• Low solubility 
• Less stability. 
Niosomes: 
Niosomes are a novel drug delivery system, in which the medication is encapsulated in a 
vesicle. The vesicle is composed of a bilayer of non-ionic surface active agents and hence the 
name niosomes. The niosomes are very small, and microscopic in size. Their size lies in the 
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nanometric scale. Although structurally similar to liposomes, they offer several advantages over 
them. Niosomes have recently been shown to greatly increase transdermal drug delivery and also 
can be used in targeted drug delivery, and thus increased study in these structures can provide 
new methods for drug delivery. In recent years, niosomes have been extensively studied for their 
potential to serve as a carrier for the delivery of drugs, antigens, hormones and other bioactive 
agents. Besides this, niosome have been used to solve the problem of insolubility, instability and 
rapid degradation of drugs. 
Advantages associated with Niosomes: 
• Niosomes are biodegradable, biocompatible and non immunogenic to the body. 
• Niosomes can be utilized in the delivery of wide variety of drugs as it has capability to 
entrap hydrophilic, lipophilic as well as ampiphilic drugs. 
• Niosomes shows controlled and sustained release of drugs due to depot formation  
• Niosomes show a greater bioavailability than conventional dosage forms. 
• Shape, size, composition, fluidity of niosomes drug can be controlled as and when 
required. 
• Niosomes had been effectively used in targeting drugs to various organs. 
Limitation: 
Physical instability in niosomal dispersion during storage occurs due to vesicles 
aggregations, fusion and leaking. This may leads to hydrolysis of encapsulated drugs which 
affects the shelf life of the dispersion. 
Sphinosomes: 
Liposome stability problems are of course much more severe so it is very important task 
to improve the liposomal stability. Liposomal phospholipids can undergo chemical degradation 
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such as oxidation and hydrolysis either as a result of these changes or otherwise liposome 
maintained in aqueous suspension may aggregate, fuse, or leak their content. Hydrolysis of ester 
linkage will slow at pH value close to neutral. The hydrolysis may be avoided all together by use 
of lipid which contains ether or amide linkage instead of ester linkage (such are found in 
sphingolipid) orphospholipid derivatives with the 2- ester linkage replaced by carbomoyloxy 
function. Thus sphingolipid are been nowadays used for the preparation of stable liposomes 
known as Sphinosomes. Sphinosomes may be defined as “concentric, bilayer vesicle in which an 
aqueous volume is entirely enclosed by a membranous lipid bilayer mainly composed of natural 
or synthetic sphinolipid.Sphinosomes are administered in many ways these include Parenteral 
route of administration such as intravenous, intramuscular, subcutaneous, and intra-arterial. 
Generally it will be administered intravenous or some cases by inhalation. Often it will be 
administered into a large central vein, such as the superior vena cava and inferior vena cava to 
allow highly concentrated solution to be administered into large volume and flow vessels. 
Sphinosomes may be administered orally or transdermal. In simple way we can say Sphinosomes 
is liposome which is composed of sphinolipid. 
Advantage: 
• Provide selective passive targeting to tumor tissue. 
• Increase efficacy and therapeutic index. 
• Increase stability via encapsulation. 
• Reduction in toxicity of the encapsulated agent. 
• Improve pharmacokinetic effect (increase circulation time). 
• Flexibility to couple with site specific legends to achieve active targeting. 
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Limitation: 
• Higher cost of sphingolipid hinders the preparation and use of these vesicular systems. 
• Low entrapment efficacy. 
Pharmacosomes: 
Pharmacosomes bearing unique advantages over liposome and niosome vesicles have 
come up as potential alternative to conventional vesicles. They are the colloidal dispersions of 
drugs covalently bound to lipids. Depending upon the chemical structure of the drug–lipid 
complex they may exist as ultrafine vesicular, micelles, or hexagonal aggregates. As the system 
is formed by linking a drug (pharmakon) to a carrier (soma), they are termed as Pharmacosomes. 
They are an effective tool to achieve desired therapeutic goals such as drug targeting and 
controlled release. The criterion for the development of the vesicular Pharmacosomes is 
dependent on surface and bulk interactions of lipids with drug. Any drug possessing an active 
hydrogen atom (- COOH, -OH, -NH2, etc.) can be esterifies to the lipid, with or without spacer 
chain that strongly result in an ampiphilic compound, which will facilitate membrane, tissue, or 
cell wall transfer, in the organism. The prodrug conjoins hydrophilic and lipophilic properties, 
thus acquires ampiphilic characters, and therefore found to reduce interfacial tension, and at 
higher concentrations exhibits geomorphic behavior. 
Advantage: 
• As drug is covalently bound, membrane fluidity has no effect on release rate, but in turn 
depends upon the phase-transition temperature of the drug-lipid complex. 
• No leakage of drug take place as the drug is covalently linked to the carrier. 
• Drug can be delivered directly to the site of infection. 
• Drug release from Pharmacosomes is by hydrolysis (including enzymatic). 
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• Their degradation velocity into active drug molecule, after absorption depends very much 
on the size and functional groups of the drug molecule, the chain length of the lipids, and 
the spacer. 
• Reduced cost of therapy. 
Limitation: 
• Synthesis of a compound depends upon its ampiphilic nature. 
• Required surface and bulk interaction of lipids with drugs. 
• Required covalent bonding to protect the leakage of drugs. 
• Pharmacosomes, on storage, undergo fusion and aggregation, as well chemical 
hydrolysis. 
Transferosomes: 
Transferosomes was introduced for the effective transdermal delivery of number of low 
and high molecular weight drugs. Transferosomes can penetrate the intact stratum corneum 
spontaneously along two routes in the intracellular lipid that differ in their bilayer properties. It 
consist of both hydrophilic and hydrophobic properties, high deformability gives better 
penetration of intact vesicles. These vesicular Transferosomes are several orders of magnitudes 
more elastic than the standard liposomes and thus well suited for the skin penetration. 
Transferosomes overcome the skin penetration difficulty by squeezing themselves along the 
intracellular sealing lipid of the stratum corneum. There is provision for this, because of the high 
vesicle deformability, which permits the entry due to the mechanical stress of surrounding, in a 
self-adapting manner. Flexibility of Transferosomes membrane is achieved by mixing suitable 
surface-active component sin the proper ratios. Transferosomes based formulations of local 
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anesthetics- lidocaine and tetracaine showed permeation equivalent to subcutaneous injections. 
Anti cancer drugs like methotrexate were tried for transdermal delivery using Transferosomes 
technology. This provided a new approach for treatment especially of skin cancer. 
Advantage: 
• Transferosomes possess an infrastructure consisting of hydrophobic and hydrophilic 
moieties together and as a result can accommodate drug molecules with wide range of 
solubility. 
• Transferosomes can deform and pass through narrow constriction (from 5 to 10 times less 
than their own diameter) without measurable loss. 
• Possess high entrapment efficiency, in case of lipophilic drug near to 90%. 
• Used for both systemic as well as topical delivery of drug. 
Limitation: 
• Transferosomes are chemically unstable because of their predisposition to oxidative 
degradation. 
• Purity of natural phospholipids is another criteria militating against adoption of 
Transferosomes as drug delivery vehicles. 
• Transferosomes formulations are expensive. 
Future Perspective: 
Vesicular drug delivery systems are emerging with the diverse application in 
Pharmaceutics, Cosmetics and food industries. Their delivery of drug directly to the site of 
infection, leading to reduction of drug toxicity with no adverse effects. It also reduces the cost of 
therapy by imparting better biopharmaceutical properties to the drug, resulting in improved 
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bioavailability, especially in case of poorly soluble drugs. Now a day’s various non-steroidal anti 
inflammatory drugs, proteins, cardiovascular, antineoplastic, antiglucoma, ant diabetic drugs that 
are incorporated with vesicular system are available in a commercial market that are playing a 
vital role to cure from a disease, hence improving the health of human kinds. Some of the 
emerging vesicular drug delivery system is listed below. 
 
CHAPTER III                                                    NIOSOMES REVIEW  
 
19 
 
CHAPTER III 
NIOSOMES-REVIEW 
Niosomes or non-ionic surfactant vesicles are microscopic lamellar structures formed on 
admixture of non-ionic surfactant of the alkyl or dialkyl polyglycerolether class and cholesterol 
with subsequent hydration in aqueous media. They are vesicular systems similar to liposomes 
that can be used as carriers of ampiphilic and lipophilic drugs. The method of preparation of 
niosome is based on liposome technology. The basic process of preparation is the same i.e. 
hydration by aqueous phase of the lipid phase which may be either a pure surfactant or a mixture 
of surfactant with cholesterol. After preparing niosomal dispersion, unentrapped drug is 
separated by dialysis centrifugation or gel filtration. A method of in-vitro release rate study 
includes the use of dialysis tubing. Niosomes are promising vehicle for drug delivery and being 
non-ionic; it is less toxic and improves the therapeutic index of drug by restricting its action to 
target cells. Niosomes are unilamellar or multilamellar vesicles formed from synthetic non-ionic 
surfactants. They are very similar to the liposomes. Niosomal drug delivery is potentially 
applicable to many pharmacological agents for their action against various diseases. Niosomes 
have shown promise in the release studies and serve as a better option for drug delivery system. 
This class of vesicles was introduced by Handjani – Vila et al. They are vesicular systems 
similar to liposomes that can be used as carriers of ampiphilic and lipophilic drugs (Thersa, 
1998). One of the reasons for preparing niosomes is the assumed higher chemical stability of the 
surfactants than that of phospholipids, which are used in the preparation of liposomes. Due to the 
presence of ester bond, phospholipids are easily hydrolyzed (Breimer, 1985). Unreliable 
reproducibility arising from the use of lecithin’s in liposomes leads to additional problems and 
has led scientist to search for vesicles prepared from other material, such as non-ionic 
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surfactants. Niosomes are promising vehicle for drug delivery and being non-ionic; it is less 
toxic and improves the therapeutic index of drug by restricting it suction to target cells.  
Niosomes or non-ionic surfactant vesicles are microscopic lamellar structures formed on 
admixture of non-ionic  
FIGURE 2: Structure of niosome vesicle 
Surfactant of the alkyl or dialkyl polyglyceryl ether class and cholesterol with 
subsequehydration in aqueous media. (Malhotra) In niosomes, the vesicles forming ampiphilic is 
a non-ionic surfactant such as Span – 60 which is usually stabilized by addition of cholesterol 
and small amount of anionic surfactant such as dicetyl phosphate. The first report of non-ionic 
surfactant vesicles came from the cosmetic applications devised by L’Oreal (Buckton et al., 
1995). The concept of incorporating the drug into niosomes for a better targeting of the drug at 
appropriate tissue destination is widely accepted by researchers and academicians. Niosomes 
represent a promising drug delivery module. They present a structure similar to liposome and 
hence they can represent alternative vesicular systems with respect to liposomes, due to the 
niosome ability to encapsulate different type of drugs within their multi environmental structure 
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(Don et al., 1997).Niosomes are thoughts to be better candidates drug delivery as compared to 
liposomes due to various factors like cost, stability etc. Various types of drug deliveries can be 
possible using niosomes like targeting, ophthalmic, topical, parental, etc (Handjani et al., 1979; 
Pranshu Tangri et al., 2011). 
ADVANTAGES OF NIOSOMES 
• The niosomal drug delivery is a potential drug delivery method for controlled and 
targeted drug delivery; the major advantages of these vesicular drug carriers are; 
• Niosomal dispersion in an aqueous phase can be emulsified in a non-aqueous phase to 
regulate the delivery rate of drug and administer normal vesicle in external non aqueous 
phase. 
• The vesicle suspension is water–based vehicle. This offers high patient compliance in 
comparison with oily dosage forms. 
• They are osmotically active and stable, as well as they increase the stability of entrapped 
drug. 
• Handling and storage of surfactants requires no special conditions. 
• They improve oral bioavailability of poorly absorbed drugs and enhance skin penetration 
of drugs. 
• They can be made to reach the site of action by oral, Parenteral as well as topical routes. 
• The surfactants are biodegradable, biocompatible and non-immunogenic. 
• They improve the therapeutic performance of the drug molecules by delayed clearance 
from the circulation, protecting the drug from biological environment and restricting 
effects to target cells. 
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• Niosomal dispersion in an aqueous phase can be emulsified in a non-aqueous phase to 
regulate the delivery rate of drug and administer normal vesicle in external non-aqueous 
phase. 
• Niosomes possess an infrastructure consisting of hydrophilic, ampiphilic and lipophilic 
moieties to gather and as a result can accommodate drug molecules with a wide range of 
solubility’s. 
• The characteristics of the vesicle formulation are variable and controllable. Altering 
vesicle composition, size, lamellarity, tapped volume; surface charge and concentration 
can control the vesicle characteristics. 
• The vesicles may act as a depot, releasing the drug in a controlled manner. 
• They improve the therapeutic performance of the drug molecules by delayed clearance 
from the circulation, protecting the drug from biological environment and restricting 
effects to target cells. 
FACTORS GOVERNING NIOSOME FORMATION: 
Amount and type of surfactant 
The mean size of niosomes increases proportionally with increase in the HLB of 
surfactants like Span85 (HLB 1.8) to Span20 (HLB 8.6) because the surface free energy 
decreases with an increase in hydrophobicity of surfactant. Theoretically niosome formation 
requires the presence of a particular class of ampiphilic and aqueous solvent. In certain cases 
cholesterol is required in the formulation and vesicle aggregation for example may be prevented 
by the inclusion of molecules that stabilize the system against the formation of aggregates by 
repulsive stearic or electrostatic effects .The bilayer of the vesicles are either in the so called 
liquid state or in gel state, depending on the temperature, the type of lipid or surfactant and the 
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presence of other components such as cholesterol. In the gel state, alkyl chains are present in a 
well ordered structure, and in the liquid state, the structure of the bilayer is more disordered. The 
surfactants and lipids are characterized by the gel liquid phase transition temperature (TC). Phase 
transition temperature also affects entrapment efficiency.eg:span 60 is the better surfactant 
because it is having high phase transition temperature and low HLB value so it form vesicle of 
good size without micelle formation (D.Akhilesh et al., 2012). 
Cholesterol content and charge: 
Inclusion of cholesterol in niosomes increases its hydrodynamic diameter and entrapment 
efficiency. In general, the action of cholesterol is two folds; on one hand, cholesterol increases 
the chain order of liquid-state bilayer and on the other, cholesterol decreases the chain order of 
gel state bilayer. At a high cholesterol concentration, the gel state is transformed to a liquid-
ordered phase an increase in cholesterol content of the bilayer resulted in a decrease in the 
release rate of encapsulated material and therefore an increase of the rigidity of the bilayer 
obtained. Presence of charge tends to increase the interlamellar distance between successive 
bilayer in multi lamellar vesicle structure and leads to greater overall entrapped volume. The 
level of surfactant/lipid used to make niosomal dispersions is generally 10-30 mM (1- 2.5% 
w/w).Altering the surfactant: water ratio during the hydration step may affect the system's 
microstructure and hence the system's properties. However increasing the surfactant/lipid level 
also increases the total amount of drug encapsulated, although highly viscous systems result, if 
the level of surfactant/lipid is too high. 
Nature of the encapsulated drug: 
Entrapment of drug in niosomes increases vesicle size, probably by interaction of solute 
with surfactant head groups, increasing the charge and mutual repulsion of the surfactant bilayer, 
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thereby increasing vesicle size. E.g.: DOX has been shown to alter the electrophoretic mobility 
of hexadecyldiglycerol ether (C16G2) niosomes in a pHdependent manner, an indication that the 
amphipathic drug is incorporated in the vesicle membrane. 
Structure of surfactants 
The geometry of vesicle to be formed from surfactants is affected by its structure, which 
is related to critical packing parameters. On the basis of critical packing parameters of 
Surfactants can predicate geometry of vesicle to be formed. Critical packing parameters can be 
defined using following equation, 
CPP = V/LC×a0 
Where, 
CPP ≤ 0.5 micelles form 
CPP = 0.5 – 1 spherical vesicles form 
CPP = ≥ 1 inverted vesicles form 
V     =  Hydrophobic group volume 
Lc    = the critical hydrophobic group length,, 
a0    = the area of hydrophilic head group. 
Span 60 is the good surfactant because it has CPP value between 0.5 to 1 
Temperature of hydration 
Hydration temperature influences the shape and size of the noisome. The hydrating 
temperatures used to make niosomes should usually be above the gel to liquid phase transition 
temperature of the system. 
 
 
CHAPTER III                                                    NIOSOMES REVIEW  
 
25 
 
TYPES OF NIOSOMES
 
  They are divided in to three types  
• Multilamellar niosomes (>0.05µm)   
• Small unilamellar niosomes (0.025-0.05µm) 
• Large unilamellar niosomes (>0.01µm) 
 
Figure 3: Schematic illustration of different size and number of lamellae 
       SUV: Small unilamellar vesicles LUV: Large unilamellar vesicles 
        MLV: Multilamellar vesicles, MVV: Multi vesicular vesicles. 
Method of preparation of niosomes 
Various methods are reported for the preparation of niosomes such as:  
1. Ether injection method  
2. Hand shaking method (Thin film hydration technique)  
3. Sonication method  
4. Reverse phase evaporation technique (REV)  
5. Micro fluidization  
6. Multiple membrane extrusion method  
7. Trans membrane pH gradient (inside acidic) drug uptake process (remote loading)  
8. Bubble method  
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9. Formation of niosomes from proniosome  
1. Ether injection method  
This method provides a means of making niosomes by slowly introducing a solution of 
surfactant dissolved in diethyl ether (volatile organic solvent) into warm water maintained at 
60°C. The surfactant mixture in ether is injected through 14- gauge needle into an aqueous 
solution of material. Vaporization of ether (volatile organic solvent) leads to formation of single 
layered vesicles. Depending upon the conditions used the diameter of the vesicle range from 50 
to 1000 nm (Raj. K. Keservani et al., 2011).  
2. Hand shaking method (Thin film hydration technique)  
The mixture of vesicles forming ingredients like surfactant and cholesterol are dissolved 
in a volatile organic solvent (diethyl ether, chloroform or methanol) in a round bottom flask. The 
organic solvent is removed at room temperature (20°C) using rotary evaporator leaving a thin 
layer of solid mixture deposited on the wall of the flask. The dried surfactant film can be 
rehydrated with aqueous phase at 0-60°C with gentle agitation. This process forms typical 
multilamellar niosomes.  
3. Sonication  
In this method an aliquot of drug solution in buffer is added to the surfactant/cholesterol 
mixture in a 10-ml glass vial. The mixture is probe sonicated at 60°C for 3 minutes using a 
Sonicator with a titanium probe to yield niosomes.  
4. Reverse phase evaporation technique (REV)  
Cholesterol and surfactant (1:1) are dissolved in a mixture of ether and chloroform. An 
aqueous phase containing drug is added to this and the resulting two phases are sonicated at 4- 
5°C. The clear gel formed is further sonicated after the addition of a small amount of phosphate 
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buffered saline (PBS). The organic phase is removed at 40°C under low pressure. The resulting 
viscous niosome suspension is diluted with PBS and heated on a water bath at 60°C for 10 min 
to yield niosomes.  
5. Micro fluidization  
It is a recent technique used to prepare unilamellar vesicles of defined size distribution. 
This method is based on submerged jet principle in which two fluidized streams interact at ultra 
high velocities, in precisely defined micro channels within the interaction chamber. The 
impingement of thin liquid sheet along a common front is arranged such that the energy supplied 
to the system remains within the area of niosomes formation. The result is a smaller size, greater 
uniformity and better reproducibility of niosomes formed.  
6. Multiple membrane extrusion method  
Mixture of surfactant, cholesterol and dicetyl phosphate in chloroform is made into thin 
film by evaporation. The film is hydrated with aqueous drug polycarbonate membranes, solution 
and the resultant suspension extruded through which are placed in series for up to 8 passages. 
Multiple membrane extrusion method is better for the controlling of niosome size.  
7. Trans membrane pH gradient (inside acidic) drug uptake process (remote loading)  
Surfactant and cholesterol are dissolved in chloroform. The solvent is then evaporated 
under reduced pressure to get a thin film on the wall of the round bottom flask. The film is 
hydrated with 300 mM citric acid (pH 4.0) by vortex mixing. The multilamellar vesicles are 
frozen and thawed 3 times and later sonicated. To this niosomal suspension, aqueous solution 
containing 10 mg/ml of drug is added and vortexed. The pH of the sample is then raised to 7.0-
7.2 with 1M disodium phosphate. This mixture is later heated at 60°C for 10 minutes to give 
niosomes.  
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8. Bubble method  
It is novel technique for the one step preparation of liposomes and niosomes without the 
use of organic solvents. The bubbling unit consists of round-bottomed flask with three necks 
positioned in water bath to control the temperature. Water-cooled reflux and thermometer is 
positioned in the first and second neck and nitrogen supply through the third neck. Cholesterol 
and surfactant are dispersed together in this buffer (pH 7.4) at 70°C, the dispersion mixed for 15 
seconds with high shear homogenizer and immediately afterwards “bubbled” at 70°C using 
nitrogen gas.  
9. Formation of niosomes from proniosome  
Another method of producing niosomes is to coat a water-soluble carrier such as sorbitol 
with surfactant. The result of the coating process is a dry formulation. In which each water-
soluble particle is covered with a thin film of dry surfactant. This preparation is termed 
“Proniosome”.  
SEPARATION OF UNENTRAPPED DRUG  
1) Dialysis: The aqueous niosomal dispersion is dialyzed in dialysis tubing against phosphate 
buffer or normal saline or glucose solution.  
2) Gel Filtration: The unentrapped drug is removed by gel filtration of niosomal dispersion 
through a Sephadex-G-50 column and elution with phosphate buffered saline or normal saline.  
3) Centrifugation: The niosomal suspension is centrifuged and the supernatant is separated. The 
pellet is washed and then resuspended to obtain a niosomal suspension free from unentrapped 
drug (Sudhamani.T. et al., 2010). 
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CHARACTERISTATION OF NIOSOMES:  
Entrapment efficiency 
After preparing niosomal dispersion, unentrapped drug is separated by dialysis, 
centrifugation, or gel filtration and the drug remained entrapped in niosomes is determined by 
complete vesicle disruption using 50% n-propanol or 0.1% Triton X-100 and analyzing the 
resultant solution by appropriate assay method for the drug.  
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Vesicle diameter  
Niosomes assume spherical shape and so their diameter can be determined using light 
microscopy, photon correlation microscopy and freeze fracture electron microscopy.  
In-vitro release  
A method of in-vitro release rate study includes the use of dialysis tubing. A dialysis sac 
is washed and soaked in distilled water. The vesicle suspension is pipetted into a bag made up of 
the tubing and sealed. The bag containing the vesicles is placed in 200 ml of buffer solution in a 
250 ml beaker with constant shaking at 25°C or 37°C. At various time intervals, the buffer is 
analyzed for the drug content by an appropriate assay method (Sakthivel M. et al., 2012). 
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Table No: 1 Analytical method for characterizing niosomes (Rekha Rao et al., 2011). 
 
S.NO. 
 
PARAMETER(S) 
 
METHOD(S) 
1. Morphology 
Transmission Electron Microscopy, Scanning 
Electron Microscopy, Optical 
Microscopy(OM), Cryo- Scanning Electron 
Microscopy, Freeze Fracture Microscopy. 
2. 
Vesicle size determination 
and Size distribution 
Dynamic Light Scattering using particle Size 
Analyzer(PSA), Malvern Master Sizer, Photon 
Correlation Spectroscopy (PCS), OM, SEM, 
Laser Diffraction PSA. 
3. 
Zeta potential/ Surface 
Charge 
Micro-electrophoresis meter, High Performance 
Capillary electrophoresis and Malvern Zeta 
Sizer (Zeta meter) 
4. 
Rheological Properties 
(Elasticity) 
Ostwald U-tube, Low shear Rheo Analyzer & 
Extrusion method. 
5. 
Micro viscosity of 
niosomal membrane 
Spectroflurophotometer 
6. Viscosity Ostwald’s viscometer 
7. 
Membrane micro-
structure 
Negative Staining TEM. 
8. Lamellarity OM, TEM 
9. 
Bilayer spacing and 
thickness 
X-Ray Scattering Analysis. 
 
10. 
Gel-Liquid transition 
temperature & Thermal 
Analysis 
Differential Scanning Calorimetry, Differential 
Thermal Analysis, & Hot Stage Microscopy. 
11. Circular Dichroism Spectropolarimeter. 
12. 
Micro polarity 
measurement 
Fluorescence Spectrophotometer. 
13. Fluidity of vesicles Differential Polarized Phase Fluorimetry 
14. Turbidity measurement UV-Visible Diode Array Spectrophotometer. 
15. Entrapment Efficiency 
Centrifugation method, Dialysis method, Gel 
Exclusion Chromatography. 
16. In-vitro release rate Using dialysis membrane. 
17. Permeation study Franz Diffusion Cell. 
18. Conductivity Conduct meter 
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TOXICITY AND STABILITY
 
Non-ionic surfactants used in niosomes are non-toxic and no toxic effects have been 
reported so far in animal studies due to the use of niosomes as drug carriers. Jain et al didn’t 
observe any morphological changes on storage for three months. Baille et al determined the 
stability in buffer and reported that the amount of entrapped solute would be retained under long 
term storage conditions. 
Comparison of Niosome v/s Liposome 
Niosomes are different from liposomes in that they offer certain advantages over 
liposomes. Liposomes face problems such as they are expensive, their ingredients like 
phospholipids are chemically unstable because of their predisposition to oxidative degradation, 
they require special storage and handling and purity of natural phospholipids is variable. 
Niosomes do not have any of these problems. Also since niosomes are made of uncharged 
single-chain surfactant molecules as compared to the liposomes which are made from neutral or 
charged double chained phospholipids, the structure of niosomes is different from that of 
liposomes. However Niosomes are similar to liposomes in functionality. Niosomes also increase 
the bioavailability of the drug and reduce the clearance like liposomes. Niosomes can also be 
used for targeted drug delivery, similar to liposomes. As with liposomes, the properties of the 
niosomes depend both- on the composition of the bilayer, and the method of production used 
(Stuti Gupta et al., 2011). 
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CHAPTER IV 
TOPICAL DRUG DELIVERY SYSTEM 
  Over the last decades the treatment of illness has been accomplished by 
administrating drugs to human body via various routes namely oral, sublingual, rectal, 
parental, topical, inhalation etc. Topical delivery can be defined as the application of a drug 
containing formulation to the skin to directly treat cutaneous disorders like acne or the 
cutaneous manifestations of a general disease like psoriasis with the intent of containing the 
pharmacological or other effect of the drug to the surface of the skin or within the skin. Semi-
solid formulation in all their diversity dominate the system for topical delivery, but foams, 
spray, medicated powders, solution, and even medicated adhesive systems are in use. The 
delivery of a drug to a specific site, topical formulations are probably among the most 
challenging products to develop. An effective topical formulation needs to provide a stable 
chemical environment in a suitable dispensing container in order to accommodate multiple 
compounds that may have different, if not incompatible, physicochemical characteristics. 
Once applied, a topical formulation must interact with the skin environment, which can 
influence the rate of the release of the compounds in order to achieve adequate skin 
absorption (Imran K. Tadwee et al., 2012). 
The excipients themselves will exert additional physical effects on the skin, such as 
drying, occluding, or moisturizing. Research and technology have brought a better 
understanding of the physics, chemistry, pharmacodynamic, and pharmacokinetics for drugs 
used to treat acne. These insights have resulted in new delivery systems that are capable of 
enhancing the efficacy, tolerability, and cosmetic acceptability of topical formulations. 
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Topical drug delivery offers the advantages of ease of delivery, a cooperative patient, 
increased compliance as well as the avoidance of first-pass metabolism. Disadvantages are 
the lack of, or reduced rates of absorption and cosmetic considerations. New drug delivery 
technology and penetration enhancers may help to obviate some of these objections. There 
are important issues to consider as you contemplate development of a topical dermatological 
product. You may already have experience with oral or Parenteral products, but there are 
challenges and issues which are unique to development of topical formulations.  
       A topical formulation must be aesthetically pleasing, in addition to being both physically 
and chemically stable, and this may require numerous excipients. The formulation must allow 
for optimal penetration of the drug into the skin, a complex tissue. Skin pH is approximately 
5.5; thus the pH of the formulation may change following application to the skin. 
        A successful topical dermatological formulation can be considered to be one that 
satisfies the target product profile and is 1)Physically and chemically stable having adequate 
shelf life, 2) Releases drug from the formulation and delivers it into the skin as required for 
the target indication, 3) Is cosmetically elegant and acceptable to patients, 4) Contains only 
excipients that are necessary,FDA approved or acceptable from a regulatory perspective, and 
acceptable for the disease state,5) Is easy to apply and compatible with the desired packaging, 
and 6) Can be manufactured with a process that is scalable to commercial levels. There are 
challenges during almost every development program. It is important to be able to anticipate 
problems, prevent them where possible, and to understand how to correct those that do occur. 
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SKIN
 
 
Skin is the largest organ of 1.5 to 2 m
2
 in adult which covers the whole body.  
Thickness of skin varies from place to place i.e.; it is so thick in palm, foot and so thin in 
eyelid. (K.J.W.wilson and Anne lalaugh 1999,).
 
 
FIGURE 4: Structure of skin 
The skin is broadly classified into two layers. They are;  
A) Epidermis  
B) Dermis. 
A. Epidermis 
 It is the most superficial (or) outermost layer of skin. The cells in the epidermis shed 
periodically and replaced by new cells usually a complete replacement of epidermis takes 
about 40 days. 
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Various Layers in Epidermis  
There are about four layers. They are;  
1. Stratum corneum. 
2. Stratum lucidum. 
3. Stratum granulosm.  
4. Germinative layer 
B. Dermis 
 Dermis consists of the following things in it  
1. Blood vessels. 
2. Lymph vessels. 
3. Sensory (somatic) nerve ending. 
4. Sweat glands and their ducts. 
5. Hair roots, hair follicles and hairs. 
6. The arrectores pilorum – involuntary muscles attached to the hair follicles. 
7. Sebaceous glands. 
Hairs, secretions from sebaceous glands and ducts of sweat glands pass via the epidermis 
to reach the surface.  
FUNCTION OF SKIN  
 It does major functions to the human body. They are; 
• Mechanical function  
• Protective function  
Microbiological barrier 
Chemical  barrier 
Radiation barrier  
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Electrical Barrier  
• Regulation of body temperature 
• Formation of vitamin D 
• Sensation 
• Absorption  
• Excretion  
RATIONAL APPROACH TO DELIVER THE DRUG VIA SKIN 
 
FIGURE 5 
There are three main ways to approach the problem of formulating a successful topical 
dosage form. (M.E.Aulton, 2004). 
• Manipulating the barrier function of the skin  
• Directing drugs to the viable skin tissues without using oral, systemic (or) other 
routes.  
• Using skin delivery for systemic treatment.  
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Dermatologist aim five main target regions. They are skin surface, horny layer, viable 
epidermis & upper dermis, skin glands and systemic circulation.  
 
FIGURE 6 
FACTORS AFFECTING DRUG DELIVERY  
Transdermal route should have the capability to deliver the drug, regardless of size 
(or) structure at a predetermined rate. But there are some factors which influence the rate of 
drug delivery.  There are two types of factors. 
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A. Biological factors  
Skin condition.  
Skin age. 
Amount of blood flow. 
Regional Skin sites. 
Skin metabolism. 
Species differences. 
B. Physiochemical Factors  
Skin hydration. 
Temperature and pH 
Diffusion Coefficient 
Drug applying surface area. 
Drug Concentration. 
Partition Coefficient.  
Molecular size and shape. 
TYPES OF TREATMENT ACHIEVED BY TOPICAL DRUG DELIVERY  
Camouflage. 
Protection effects 
Insect repellant. 
Antimicrobial. 
Antifungal. 
Emolliency.  
Keratosis. 
Antiperspirant. 
Exfolient. 
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Antibiotic. 
Depilatory. 
Anti inflammation. 
Anti pruritic. 
Local anesthetic. 
PUFA and PDT. 
Anti histamine. 
Anti angina. 
Anti-ischemic. 
VARIOUS TYPE OF DOSAGE FROM USED IN TOPICAL DRUG DELIVERY 
Liquid preparations. 
Gels (jellies). 
Powders. 
Ointments. 
Creams. 
Paste. 
Aerosols. 
Poultice. 
Transdermal patch. 
ROLE OF NIOSOMES IN TRANSDERMAL DRUG DELIVERY SYSTEM 
Niosomes can be used to deliver both hydrophobic and hydrophilic drugs via topical 
route. Although niosomes were tried for various routes it is used in the market for topical 
route . Studies showed that an enhanced delivery of drugs when encapsulated in niosomes. 
Niosomes increase skin penetration of drugs and it can act as local depot for sustained release 
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of dermal active compounds. When non ionic surfactants are incorporated into niosomes they 
are much better tolerated by the skin then when they are used in emulsion.   
NON-STERODIAL ANTI-INFLAMMATORY DRUGS 
Non-steroidal anti-inflammatory drugs, usually abbreviated to NSAIDs or NAIDs are 
drugs with analgesic and antipyretic effects and which have, in higher doses, anti-
inflammatory effects. The term nonsteroidal is used to distinguish these drugs from steroids, 
which have a similar eicosanoid-depressing, anti-inflammatory action. As analgesics, 
NSAIDs are usually in that they are non-narcotic. The most prominent members of this group 
of drugs are aspirin, ibuprofen and naproxen partly because they are available over the 
counter in many areas. (Tanu Bhargava et al., 2011). 
Mechanism of action: 
Most NSAIDs act as nonselective inhibitors of the enzyme cyclooxygenase (COX), 
inhibiting both the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes. 
COX catalyzes the formation of prostaglandins and thromboxane form arachidonic acid. 
Prostaglandins act as messenger molecules in the process of inflammation .This mechanism 
of action was elucidated by John Vane (1927- 2004), who later received a Nobel Prize for 
this work. NSAIDs have antipyretic activity and can be used to treat fever. Fever is caused by 
elevated levels of prostaglandin E2, which alters the firing rate of neurons within the 
hypothalamus, that control thermoregulation. Antipyretics work by inhibiting the enzyme 
COX, which causes the general inhibition of prostanoid biosynthesis (PGE2) within the 
hypothalamus. PEG2 signals to the hypothalamus to increase the body’s thermal set point. 
Ibuprofen has been shown to be more effective as an antipyretic than acetaminophen. 
Arachidonic acid is the precursor substrate for cyclooxygenase leading to the production of 
prostaglandins F, D and E. 
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Classification: 
NSAIDs can be broadly classified based on their chemical structure; 
1) Prpoionic acid derivatives 
Ibuprofen 
Naproxen 
Ketoprofen 
Flurbiprofen. 
2) Acetic acid derivatives 
Indomethacin 
Diclofenac. 
3) Enolic acid derivatives 
Piroxicam 
Meloxicam 
Lornoxicam. 
4)  Fenamic acid derivatives 
Mefenamic acid 
Tolfenamic acid 
5) Selective COX-2 inhibitors 
Celecoxib 
Valdecoxib 
Etoricoxib 
USES: 
Rheumatoid arthritis 
Osteoarthritis 
Acute gout 
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Metastatic bone pain 
Postoperative pain 
Pyrexia 
Renal colic 
ADVERSE EFFECTS: 
The two main adverse drug reaction associated with NSAIDs relate to gastrointestinal 
effects and renal effects of the agents. These effects are dose-dependent, and in many cases 
severe enough to pose the risk of ulcer perforation, upper gastrointestinal bleeding, and death 
limiting the use of NSAIDs therapy.  
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CHAPTER-V 
LITERATURE REVIEW 
Vijay S. Jatav et al., 2010.  The niosomes containing rifampicin were prepared using various 
non ionic surfactants of sorbitan ester class and cholesterol in 50:60 percent mol fraction ratios 
for sustain release. To improve the dissolution rate of niosomes prepared by hand shaking 
method. The entrapment efficiency was decrease progressively span-85>span-80>span-60>span-
40>span-20. The invitro release rate studies given span-20 maximum cumulative percent and 
span-85 minimum cumulative percent. The handshaking method is a simple and efficient 
technique for designing functional niosomes for hydrophobic or ampiphilic drugs. 
Lakshmi.P.K et al., 2009. The niosomes containing salbutamol sulphate was prepared using 
span 60 as the surfactant. In this niosomes prepared by various techniques. The drug 
encapsulation efficiency varied from 62% to 87%.Transmembrane pH gradient method was 
found to be most satisfactory which released 78.4% of drug in 24h.Tissue distribution studies in 
albino rats and bio availability studies in rabbits were carried out. 
 Anand Kumar.Y et al., 2011.  Aceclofenac is a drug with narrow therapeutic index and short 
biological half-life. This study was optimizing niosomal formulation of Aceclofenac in order to 
improve its bioavailability. The noisome formulation were evaluated particle size, entrapment 
efficiency and drug release were studied. The in vitro release studies used the dialysis membrane. 
The mechanism of drug release was governed by Peppas model. 
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Ibrahim A. Alsarra et al., 2005. Having a considerable ability to improve the permeability of 
drugs through lipid membranes, niosomes have been utilized as carriers to enhance atenolol 
absorption from the gastrointestinal tract. Two methods have been adopted  to prepare niosomes, 
the proniosome-derived method (A) and the conventional film hydration method (B).Their 
morphology, vesicle size, drug encapsulation efficiency, in vitro release were compared to the 
two methods. High encapsulation efficiencies of 98.6% and 93.4% were achieved by methods A 
and B, respectively. In vitro drug release has been significantly retarded from both types of 
niosomes. The release kinetics non-Fickian behavior. Permeation through an everted intestinal 
sac showed a significant enhancement perfect for both types’ niosomes. 
Vyas jigar et al., 2011 Erythromycin was entrapped into niosomes by thin film hydration 
technique and various process parameters were optimized by partial factorial design. 
Demonstrated that encapsulation of erythromycin into niosomal gel formulation improves skin 
retention which may be reflected, based on prior hypothesis, as significantly improved 
therapeutic response and considerably reduced  adverse symptom. However, the role of niosomal 
erythromycin gel of this study can only be settled after clinical evaluation of the product with 
large number of patient with special focus on the adverse symptom of the therapy. 
Srikanth.K et al., 2010 Meloxicam entrapped niosomes were prepared by thin film hydration 
technique using Nonionic surfactants (span-80, span-60, Tween-80, Tween-60), cholesterol and 
drug in different ratios. To develop a topical Meloxicam niosomal gel using non-ionic surfactants 
to avoid the side effects developed when Meloxicam taken orally. The niosomal gel showed 
better pharmacological activity than the Meloxicam plain gel indicating a promising potential of 
the Meloxicam niosomal gel as an alternative to  the conventional dosage forms. 
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Fathy I.abd-allah et al., 2010 Piroxicam in micro emulsion formulations from different 
pharmaceutical topical preparation including different gel bases such as methyl cellulose, 
carbopol 934. The usage of the micro emulsion technique led to improvement in Piroxicam 
availability which can offer many promising features for its use as a topical vehicle for 
Piroxicam delivery. In vitro release, rheological properties and shelf life, the HPMC gel base 
containing 0.5% Piroxicam in micro emulsion formula was the best among the studied 
formulations. 
Saleem.M.A et al., 2010 Solid dispersion complexes of Meloxicam were prepared by using 
cyclodextrins, PVP, and urea by kneading method in different molar and weight ratios. The 
solubility, dissolution and permeability was significantly enhanced by using solid dispersion of 
Meloxicam. Hence Meloxicam solid dispersion incorporated gel shows highest drug permeation 
through rat skin as compared 
Mahmoud Mokhtar et a1., 2008 studied the effect of some formulation parameters on 
flurbiprofen encapsulation and release rates of niosomes prepared from Proniosomes. 
Proniosomal gels or solutions of flurbiprofen were developed based on span 20, span 40,span 60, 
and span 80 without and with cholesterol. Niosomes formed immediately upon hydrating 
proniosomal formulae. The   entrapment efficiency (EE %) of flurbiprofen (a poorly soluble 
drug) was either determined by exhaustive dialysis of freshly prepared niosomes or 
centrifugation of freeze-thawed vesicles. The influence of different processing and formulation 
variables such as surfactant chain length, cholesterol content, drug concentration, total lipid 
concentration, negatively or positively charging lipids, and the pH of the dispersion medium on 
flurbiprofen EE% was demonstrated. Results indicated that the EE% followed the trend Sp 60 
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(C18)>Sp 40 (C16)>Sp 20 (C12)>Sp 80 (C18). Cholesterol increased or decreased the EE% 
depending on either the type of the surfactant or its concentration within the formulae. 
Toshimitsu Yoshioka et al.,1994 studied the formation of niosomes with a series of sorbitan 
monoesters (Span 20, 40, 60 and 80) and a sorbitan trioleate (Span 85) using a mechanical 
shaking technique without sonication. 5(6)-Carboxyfhxxescein (CFI was used as a model solute 
to investigate entrapment efficiency and release. For Span 80, cholesterol and dicetyl phosphate 
DCP) in the molar ratio 47.5: 47.5: 5.0, entrapment efficiency increased linearly with increasing 
concentration of lipid. Entrapment efficiency increased with increasing cholesterol content when 
vesicles were prepared by changing the molar ratio of non-ionic surfactant to cholesterol. Most 
efficient entrapment of CF occurred with Span 60 (HLB 4.7). Mean size of the un-sonicated 
niosomes showed a regular increase with increasing HLB from Span 85 (HLB 1.8) to Span 20 
(HLB 8.6). The release rate of CF from vesicles depended on the surfactant used in the 
preparation of the vesicles. 
Manivannan Rangasamy et al., 2008 explained the acyclovir niosome preparation with 
different ratios of (1:1, 1:2, 1:3) cholesterol and Span 80 using hand shaking and ether injection 
process. The vesicles were in size range of 0.5-5 µm (hand shaking process) and 0.5-2.5 µm 
(ether injection process). The order of entrapment efficiency increases when Span 80 
concentration was increased. In vitro release study & 16hrs for release.  
Abdul Hasan Sathali A. et al., 2010 developed terbinafine Hcl niosomes to the fungal affected 
cells for targeted delivery. Niosomes formulated by thin film hydration method using different 
ratios of non ionic surfactant (Tween 20, 40, 60, and 80) and cholesterol with constant drug 
concentration. The formulations evaluated for its vesicle size (by AFM), entrapment efficiency 
(by dialysis method) in vitro release studies and antifungal activities. The formulation with 
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surfactant cholesterol ratio 2:1 in each group of surfactant showed good entrapment. Niosomes 
tested for in vitro antifungal activity using the strain Aspergillus niger and compared with pure 
drug solution (as standard). The best (Tween 40 niosomes) formulation incorporated into gel 
bases and evaluated. 
Kandasamy Ruckmani et al., 2010 evaluated the effect of process-related variables like 
hydration time, sonication time, rotation speed of evaporation flask, changes in osmotic shock, 
viscosity, the effects of charge-inducing agent, centrifugation on entrapment and release from 
zidovudine niosomes. Formulation of zidovudine niosomes was optimized by altering the 
proportions of Tween, Span and cholesterol. Non-sonicated niosomes were in the size range of  
2-3.5 µm and sonicated niosomes had a mean diameter of 801 nm. Niosomes formulated with 
Tween 80 entrapped high amounts of drug and the addition of DCP enhanced drug release for a 
longer time (88.72% over 12 h). The mechanism of release was the Fickian type and obeyed 
first-order release kinetics.  
Tamizharasi S. et al., 2009 formulated gliclazide-loaded niosomes and evaluated for their in 
vitro as well as in vivo characteristic in an attempt to improve the oral bioavailability. 
Microscopic observation confirmed that all particles were uniform in size and shape. The 
entrapment efficiency determined dialysis method. The in vitro release studies exhibited a 
prolonged drug release over a period of 24 h. The positive values of zeta potential indicated that 
the gliclazide niosomes were stabilized by electrostatic repulsive forces. The niosomes showing 
maximum entrapment and suitable release rate were selected for in vivo evaluation.  
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Vijay Prakash Pandey et al., 2009 demonstrated the ofloxacin niosomes formation, to 
overcome ofloxacin eye drop solution drawbacks (poor bioavailability) characterization. 
Niosomes prepared by lipid film hydration method using span 60 and cholesterol (various molar 
ratios); Characterized for entrapment efficiency, in vitro drug release, surface charge, rheological 
character, physical stability, minimum inhibitory concentration, in vivo drug release and ocular 
irritation studies. The span 60: cholesterol in molar ratio of 100:60 showed higher entrapment of 
drug and released 73.77 % at 10th hr and the availability of drug in the aqueous humor was 
4.373µg/ml (Cmax), confirmed by HPLC method. The histopathology study also confirmed the 
safe use of niosomes.  
Manosroi.A et al., 2008 developed a novel elastic bilayer vesicle entrapped with NSAID, 
diclofenac diethyl ammonium (DCFD) for topical use. 18 formulations composing of DPPC or 
Tween 61 or Span 60 mixed with cholesterol and ethanol at 0–25% (v/v), by chloroform film 
method with sonication was developed. The elastic Tween 61 niosomes which gave no 
sedimentation, no layer separation, unchanged particle sizes (about 200 nm) were selected to 
entrap DCFD. Transdermal absorption through excised rat skin was performed by vertical Franz 
diffusion cell at 32±2 ◦C for 6 h. The in vivo anti-inflammatory activity was evaluated by ethyl 
phenylpropiolate (EPP)-induced rat ear edema (n = 3).  
Prabagar Balakrishnan et al., 2009 reported to improve the low skin penetration and 
bioavailability characteristics shown by topical vehicle for minoxidil. Niosomes were prepared 
with thin film hydration method using Brij, Span and cholesterol at various ratios. The prepared 
systems were characterized for entrapment efficiency, particle size, zeta potential and stability. 
Skin permeation studies were performed using static vertical diffusion Franz cells & hairless 
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mouse skin. Higher entrapment efficiency was obtained with the niosomes prepared from Span 
60, cholesterol at 1:1 molar ratio. 
Naresh Ahuja et al., 2008 prepared the niosomes containing lansoprazole (antacid and anti ulcer 
agent) by using reverse phase evaporation method. Non-ionic surfactant Span 60 was use to 
prepare the formulations. Niosomes are characterized for its entrapment efficiency, size range 
and invitro release of drug. For release study the phosphate buffered saline pH 8.6 was used and 
the samples were assayed by UV.  
Udupa N.,and Chandraprakash K.S ., 1990 examined the methotrexate (MTX) niosomes by 
preparing it using the thin film hydration method with Tween 80, 60, 40, Span 60, 40 and 20. 
The MTX- entrapped niosomes were separated from the unentrapped by dialysis. Measurement 
of niosome size was made by using a microscope with a mean diameter 4.5µm. The entrapment 
efficiency has also been observed to be greater for Span 60 and least for Tween 80 containing 
niosomes. The reason may be attributable to the increased lipophilicity of Span 60. The order of 
entrapment efficiciency increase as the lipophilicity increased. 
Pavala Rani .N. et al., 2010 studied that niosomes are vesicles mainly consisting of non-ionic 
surfactants that encloses and encompasses the drug molecules. Niosomes of rifampicin and 
gatifloxacin were prepared by lipid hydration technique using rotary flash evaporator. The 
prepared rifampicin and gatifloxacin niosomes showed a vesicle size in the range of                 
100-300nm, the entrapment efficiency were 73% and 70% respectively. The invitro release study 
showed that 98.98% and 97.74% of release of rifampicin and gatifloxacin niosomes respectively. 
The bactericidal activities of the niosomal formulation were studied by BACTEC radiometric 
method using the resistant strains (RF 8554) and sensitive strains (H37Rv) of Mycobacterium 
tuberculosis which showed greater inhibition and reduced growth index.  
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Sambhakar S et al., 2011 prepared niosomes containing cefuroxime axetil was prepared by 
film formation method by Span 40, 60 and 80 to overcome the bioavailability problem (25%).  It 
is characterized by SEM for particle size and morphology. Entrapment efficiency and release 
study was carried out by dialysis. In-vitro absorption study was carried out by everted sac 
method and also the stability study of niosomes in presence of bile salts was determined. The 
vesicle size was found to be less than 5 µm and its polydispersity index was very low. 
Entrapment efficiency was found as Span 60 > Span 40 > Span 80. The in-vitro-release study 
indicated the controlled release profile of niosomes.  
Cosco D. et al., 2009 evaluated niosomes made up of bola, Span 80 & cholesterol (2:5:2 molar 
ratio) are proposed as suitable delivery systems for the administration of 5-fluorouracil (5-FU), 
an antitumoral compound largely used in the treatment of breast cancer. The bola-niosomes, after 
sonication procedure, showed mean sizes of ~200 nm and a loading capacity of ~40% with 
respect to the amount of 5-FU added during the preparation. Similar findings were achieved with 
PEG-coated bola-niosomes. 5-FU-loaded PEG-coated and uncoated bola niosomes were tested 
on MCF-7 and T47D cells. Both bola-niosome formulations provided an increase in the 
cytotoxic effect. Confocal laser scanning microscopy studies were carried out to evaluate both 
the extent and the time-dependent bola-niosome-cell interaction. In vivo experiments on MCF-7 
xenograft tumor SCID mice models showed a more effective antitumoral activity of the 
PEGylated niosomal 5-FU at a concentration ten times lower (8 mg/kg) than that of the free 
solution of the drug (80 mg/kg) after a treatment of 30 days. 
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Ghada Abdelbary et al., 2008 investigated the feasibility of using niosomes as carriers for the 
ophthalmic controlled delivery of gentamicin sulphate. Niosomes prepared using various 
surfactants (Tween 60, Tween 80 or Brij 35), cholesterol and a negative charge inducer DCP in 
different molar ratios by thin film hydration technique. The entrapment efficiency determined by 
centrifugation. Photomicroscope, TEM and particle size analysis used to study the morphology 
and size of niosomes. Ocular irritancy test performed on albino rabbits, showed no sign of 
irritation for all tested niosomal formulations. 
Pratap S. Jadon et al., 2009 developed griseofulvin niosomes to improve its poor and variable 
oral bioavailability. Niosomes were prepared by using span 20, span 40, and span 60. The 
formulations prepared by thin film method and ether injection method. The influence of different 
formulation variables such as surfactant type, surfactant concentration, and cholesterol 
concentration was optimized for size distribution and entrapment efficiency for both methods. 
Higher entrapment efficiency obtained with span 60 niosomes prepared by thin film method. The 
niosomal formulation exhibited significantly retarded in vitro release as compared with free 
drug. The in vivo study revealed that the niosomal dispersion significantly improved the oral 
bioavailability, AUC of griseofulvin.  
Ismail A. Attia et al., 2007 demonstrated the preparation of acyclovir niosomes in a trial to 
improve its poor and variable oral bioavailability. The niosomes were prepared by the 
conventional thin film hydration method. The % entrapment was found to be ~11%. The vesicles 
have an average size of 0.95 µm and a size range of 0.4 to 2.2 µm. Most of the niosomes have 
unilamellar spherical shape. The niosomal formulation exhibited significantly retarded release 
compared with free drug. The in vivo study revealed that the niosomal dispersion significantly 
improved the oral bioavailability (more than 2-fold increase) of acyclovir in rabbits. The 
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niosomal dispersion showed significant increase in the MRT of acyclovir reflecting sustained 
release characteristics.  
Mahmoud Mokhtar Ahmed Ibrahim et al., 2008 formulated and evaluated proniosomal 
transdermal carrier systems for flurbiprofen. Proniosomes were prepared using various              
non-ionic surfactants, namely span 20, span 40, span 60 and span 80 without and with 
cholesterol at percentages ranging from 0% to 50%. The effect of surfactant type and cholesterol 
content on drug release was investigated. Drug release was tested by diffusion through 
cellophane membrane and rabbit skin; rabbit skin showed lower drug diffusion rates compared to 
cellophane membrane. Drug release studies showed the proniosomal composition controlled 
drug diffusion rates to be either faster or slower than the prepared flurbiprofen suspensions in 
HPMC gels or distilled water, respectively. Microscopic observations showed that either 
proniosomal solutions or gel formulations immediately converted to niosomal dispersions upon 
hydration.  
Aranya Manosroi et al., 2010 studied the vesicles prepared with hydrated mixture of various 
non-ionic surfactants and cholesterol. The bilayer formation was characterized by X-cross 
formation under light polarization microscope. Membrane rigidity was measured by means of 
mobility of fluorescence probe as a function of temperatures. The stearyl chain (C18) non-ionic 
surfactant vesicles showed higher entrapment efficiency than the lauryl chain (C12) non-ionic 
surfactant vesicles. Cholesterol was used to complete the hydrophobic moiety of single alkyl 
chain non-ionic surfactants for vesicle formation.  
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Ijeoma F. Uchegbu et al., 1998 summarized the achievements in the niosomes field. A number 
of groups worldwide have studied non-ionic surfactant vesicles (niosomes) with a view to 
evaluating their potential as drug carriers. Niosomes may be formed form a diverse array of 
ampiphilic. The self assembly of surfactants into niosomes is governed by the nature of the 
surfactant, the presence of membrane additives, the nature of the drug encapsulated and the 
actual method of preparation. The influence of formulation factors on niosome stability is also 
examined. Niosomes have been evaluated as immunological adjuvant, anti-cancer: anti-infective 
drug targeting agents, carriers of anti-inflammatory drugs, in diagnostic imaging, achieve 
transdermal and ophthalmic drug delivery 
Ajay B. Solanki et al., 2010 optimized the composition of niosomes containing Aceclofenac for 
transdermal application, with a view to improve permeation of drug during an extended period of 
time. Niosomes were prepared by thin film hydration technique. A 32 factorial design was 
utilized to study the effect of the molar ratio of drug to lipid (X1) and volume of hydration 
medium (X2) on percentage drug entrapment (PDE) and vesicle size. Selected batches of 
niosomes were incorporated in to carbopol gel matrix to prepare the niosomal gel formulations, 
which were evaluated for in vitro release, skin permeation and in vivo studies. It was evident 
from the derived polynomial equations and constructed contour plot, a decrease in the level of X1 
and an increase in the X2 lead to an increase in PDE and decrease in vesicle size. The polynomial 
equations and contour plot predicted the levels of independent variables X1 and X2 (0.19 and 
0.46 respectively), for maximized response of PDE with constraints on vesicle size.  
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Toshimitsu Yoshioka et al., 1994 described in which niosomes are dispersed in an aqueous 
phase which is then emulsified in a non-aqueous continuous phase. The resultant vesicle 
(niosome) in water-in-oil (v/w/o) system allows the delivery of vesicles in a non-aqueous 
vehicle. The non-ionic surfactants used to prepare the vesicles (niosomes) are also employed in 
the emulsification step to minimize surfactant redistribution. The invitro release rate of CF 
showed a decrease in the order free solution >vesicle suspension >w/o emulsion >v/w/o 
emulsion. The release rate of CF from the v/w/o system depends on the nature of the surfactants 
used.  
Wei Hua et al., 2007 prepared highly stable innocuous niosome composed of only three 
components in Span 80/PEG 400/H2O system. The niosome properties are studied by some 
means of freeze fracture replication-transmission electron microscopy, negative staining-
transmission electron microscopy, dynamic light scattering and differential scanning 
Calorimetry. The obtained results indicate that the niosome can be stable for over one year. The 
niosome diameter is between 100 and 180 nm. The compositions of the system affect the 
preparation and properties of the niosome. 
Behrooz Nasseri et al., 2005 explained the effect of cholesterol and temperature on the elastic 
properties of niosomal membranes. The mechanical characteristics of non-ionic bilayer 
membranes composed of span 60, cholesterol and poly-24- oxyethylene cholesteryl were studied 
by measuring the modulus of surface elasticity (µ), a measure of membrane strength, as a 
function of cholesterol content and temperature. The modulus of surface elasticity increased 
slowly with increasing cholesterol concentration, with a sharp increase around 40 mol% 
cholesterol and displayed a maximum around 47.5 mol% cholesterol. Further cholesterol resulted 
in a decrease in µ. Generally, the interaction of cholesterol with the span 60 should increase the 
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rigidity of the membrane. However, the latter effect may be due to the formation of cholesterol 
clusters at high cholesterol content where excess amounts of cholesterol cannot interact with the 
sorbitan monostearate, and deposits on the bilayer compromising their uniformity, strength and 
permeability.  
Prasun Bandyopadhyay et al., 2007 studied of the self-organization of nonionic surfactant span 
60 in presence of fatty alcohol (stearyl, cetyl and lauryl) is presented. When ethanol solution of 
the surfactant–fatty alcohol (1:1) mixture is added in water spontaneous large unilamellar 
vesicles (LUV) are formed. Vesicular suspension has been characterized by transmission 
electron microscopy, dynamic light scattering, and confocal laser scanning microscopy, dye 
entrapment and release studies. 
 Chandra. A et al., 2008    Piroxicam are a widely used potent non-steroidal anti-inflammatory 
drug, with due potential for dermal delivery. Permeation of Piroxicam from proniosome based 
reservoir type transdermal gel formulation across excised rat abdominal skin was investigated 
using Keshery Chein diffusion cell. The lipid vesicles were evaluated for entrapment efficiency 
and vesicle size of niosomes formed. It was observed that Span 60 based formulations produced 
vesicles of smallest size and higher entrapment efficiency while those of Span80 produced 
vesicles of least entrapment efficiency. Incorporation of lecithin further enhanced entrapment 
efficiency. Proniosome were prepared by conventional technique and employing maltodextrin 
and sorbitol as base. The morphology of the proniosome was studied by scanning electron 
microscopy. Anti-inflammatory studies revealed that proniosome based transdermal drug 
delivery system of Piroxicam were promising carriers for delivery of Piroxicam. There was 
significant reduction in carrageenam induced rat paw inflammation compared to control. 
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Abdul Hasan Sathali.A et al., 2011. The aim of the present study was to formulate topical gel 
containing clobetasol propionate niosomes to prolong the duration of action and prevent its side 
effects. The clobetasol propionate niosomes were prepared by altering the ratios between various 
non-ionic surfactants (Span 40, 60, 80) and cholesterol by three methods such as thin film 
hydration method, ether injection method and hand shaking method. The prepared niosomes 
were subjected to drug content analysis, Entrapment efficiency, size analysis and invitro drug 
release studies. The higher entrapment efficiency (91.37%) was obtained with Span 60 niosomes 
(ratio of surfactant, cholesterol 1: 0.5) prepared by thin film hydration method was evaluated for 
its stability and formulated as gel formulation. The prepared niosomal gel (G2) and marketed gel 
(G3) were subjected to drug content analysis, in vitro drug release studies and in vivo 
pharmacodynamic studies. The results suggested that the niosomal delivery of clobetasol 
propionate in carbopol gel base acts as a suitable topical drug delivery system to prolong the 
duration of action. 
Chawda Himmat Singh et al., 2011 The niosomes provides several important advantages over 
conventional drug therapy. The main objective of this study was to design suitable niosome 
encapsulated drug delivery for anti-inflammatory drugs like nimesulide and evaluate the vesicle 
size, encapsulation efficiency, in vitro release and physical stability of the system. Non-ionic 
surfactants used were span 20, 40, 60 and cholesterol was used in different molar ratios. The 
niosomes prepared by lipid film hydration method were multilamellar vesicles (MLVS) and 
niosomes prepared by ether injection technique were unilamellar vesicles (ULVS) 
oroligolamellar vesicles. The higher entrapment efficiency was observed with MLVS prepared 
from span 60 and cholesterol in an 80:70 molar ratio. The in vitro diffusion study suggests that 
higher entrapment efficiency was related with slow release comparatively. The release pattern 
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shown by these formulations were zero order & Higuchi diffusion controlled mechanism. The 
physical stability study show that niosomal preparation stored at refrigerated temperature for 60 
days show maximum drug retained for all the formulation compare to room temperature and 
elevated temperature conditions. Finding of all this investigation conclusively demonstrate 
prolongation of drug release at a constant and controlled rate after niosomal encapsulation of 
nimesulide.  
Biswal.S et al., 2008 Vesicles prepared from self-assembly of hydrated non-ionic surfactants 
molecules are called niosomes.  Niosomes exhibit more chemical stability than liposomes as 
non-ionic surfactants are more stable than phospholipids. Non-ionic surfactants used in 
formation of niosomes are polyglyceryl alkyl ether, glucosyldialkyl ether, crown ether, 
polyoxyethylenealkyl ether, ester-linked surfactants, and steroid-linked surfactants and a spans, 
and tweens series. Niosomes preparation is affected by processes variables, nature of surfactants, 
and presence of membrane additives and nature of drug to be encapsulated. This review article 
presents an overview of theoretical concept of factors affecting niosome formation, techniques of 
niosome preparation, characterization of niosome, applications, limitations and market status of 
such delivery system 
Lakshmi.P.K et al., 2011 present study topical niosomal gel in chitosan were prepared using 
urea as a model drug. The urea niosomes were prepared by both lipid layer hydration and 
transmembrane pH gradient method. Niosomes were prepared and characterized for various 
physical characters. Surfactants such as spans were used with cholesterol in 1:1 molar ratio with 
5% dicetyl phosphate (DCP). The human volunteer study to test the irritancy was performed by 
human repeated insult patch test (HRIPT) test. PASI scoring was used to determine the severity 
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of the lesion. Niosomes prepared using span 60 showed a better entrapment than other spans. 
Both the niosomes showed uniform particle size distribution. SEM analysis showed smooth outer 
surface. A short-term stability studies showed that niosomal gel had better stability followed by 
niosomes prepared using transmembrane method and lipid layer hydration method. Permeation 
study of niosomal gel through the human skin showed better diffusion of drug through the skin 
and skin deposition study showed that better deposition of drug in comparison to plain gel. The 
niosomal urea gel and plain gel did not produce any irritation of the human skin. The gels were 
tested on psoriasis patients with less than 25% severity of any category of psoriasis. The 
niosomal gel produced significant reduction in the lesion (p<0.05) than plain urea gel. The 
niosomal urea gel produced greater reduction in total score and desquamation score compared to 
erythematic and infiltration score and proved that niosomal urea in chitosan gel can be used as an 
adjuvant in the treatment of psoriasis. 
Kumar et al., 2012 The purpose of this research is to design proniosomal gel drug delivery 
system of flurbiprofen in a trial to overcome the adverse effects associated with oral 
administration of the drug. This can be overcome by the use of vesicular drug delivery system. 
The potential of proniosome as a transdermal drug delivery system of flurbiprofen was 
investigated by encapsulating the drug in various formulations of proniosomal gel composed of 
various ratios of sorbitan fatty acid esters, cholesterol, prepared by coacervation-phase separation 
method. The formulated systems were characterized in vitro for size, vesicle count, drug 
entrapment, drug release profiles and vesicular stability at different storage conditions. Stability 
studies for proniosomal gel were carried out for 4 weeks. The method of proniosome loading 
resulted in an encapsulation yield of 30.6 – 75.4%. In-vitro studies showed prolonged release of 
entrapped flurbiprofen. At refrigerated conditions, higher drug retention was observed. It is 
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evident from this study that proniosome are a promising prolonged delivery system for 
flurbiprofen and have reasonably good stability characteristics.  
El-Nahas.M et al., 2008   For topical administration of Meloxicam, micro emulsion gels and lip 
gels containing either ethyl oleate or oleic acid as an oil phase was prepared. In addition, Hydro 
gel and hydro alcoholic gels containing carbopol 940 as a gelling agent were also prepared. In 
vitro drug release through cellophane membrane and permeation through the excised rabbit skin 
in Sorensen’s phosphate buffer (pH 7.4) containing 1% w/v sodium lauryl sulphate were 
performed .The influence of initial drug concentration was studied. The permeation property of 
Meloxicam from ethyl oleate micro emulsion which is the best formula achieved was studied in 
comparison to the commercially available Piroxicam gel. Moreover, the anti-inflammatory 
activity of Meloxicam, after oral and topical administration in rats was studied and compared to 
that of Piroxicam gel. The results of an in vitro drug release and its percutaneous permeation 
revealed that the ethyloleate micro emulsion gel showed the highest Results. Meloxicam gel 
(ethyl oleate micro emulsion gel 1%) showed good protection against inflammation as compared 
to FeldeneR gel in rats. 
Mettu srikanth reddy et al., 2011   Topical gels of Valdecoxib were prepared using different 
gelling agents (carbopol, HPMC, sodium alginate, sodium CMC). Formulations were evaluated 
for pH, rheological behavior, and drug content and in-vitro drug diffusion. Selected formulations 
of all the gelling agents were appeared to be non-Newtonian and showed pseudo plastic 
behavior. Drug content was high (>98%) in gels. Drug release from the carbopol gels increased 
with the increase in the concentration of propylene glycol up to 10%. However, drug release 
decreased as the concentration of the propylene glycol increased to 20%. The drug release 
CHAPTER V                                                 LITERATURE REVIEW  
 
60 
 
increased with the increase in concentration of ethanol. In case of gels containing HPMC, 
sodium alginate, sodium CMC as gelling agents, addition of Propylene glycol up to 5%, 
increased the release of drug from the gels. However, release decreased with increase in the 
concentration of Propylene glycol up to 10%. In case of HPMC gels, addition of ethanol 
decreased the release of Valdecoxib from the gels.   
Japan Patel et al., 2011   Aceclofenac, a non-steroidal anti-inflammatory drug, has been used in 
the treatment of rheumatoid arthritis and osteoarthritis. In order to decrease the gastric 
ulcerogenic effects, Aceclofenac gels have been developed. This study was conducted to develop 
a gel formulation of Aceclofenac using gelling agents: carbopol, hydroxypropylmethylcellulose, 
carboxymethylcellulose sodium and sodium alginate. Effect of penetration enhancer on the 
release has been studied. The gels were evaluated for physical appearance, rheological behavior, 
drug release and stability. The drug release from all gelling agents through a standard cellophane 
membrane was evaluated using Keshery-Chien diffusion cell. All gels showed acceptable 
physical properties concerning color, homogeneity, consistency, spread ability and pH value. 
Among all the gel formulations, carbopol showed superior drug release than followed by           
Na CMC, HPMC and sodium alginate. Drug release decreased with increase in polymer 
concentration. Drug release was not linearly proportional with the concentration of penetration 
enhancer or co-solvents. Stability studies show that the physical appearance, rheological 
properties, and drug release remained unchanged upon storage for two months at ambient 
conditions. 
Vyas Jigar et al., 2010   Niosomes, a non ionic surfactant vesicular formulation, have been 
explored extensively for topical application to enhance skin penetration as well as to improve 
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skin retention of drugs. In the present study, Benzyl peroxide was entrapped into niosomes by 
thin film hydration technique and various process parameters were optimized by partial factorial 
design. The optimized niosomal formulation was incorporated into HPMC K15 gel and 
extensively characterized for Percentage Drug Entrapment and in-vitro release performance. The 
stability of above formulation was studied at different temperatures. The present study 
demonstrated prolongation of drug release, increased drug retention into skin and improved 
permeation across the skin after encapsulation of Benzyl peroxide into niosomal topical gel.  
Chandira.R.M et al., 2010  In the present study, Adapalene gels were prepared using CMC Na, 
HPMC, HPC, Carbomer and combinations of cellulose derivatives; as base and PluronicPE-6200 
as penetration enhancer for the treatment of Acne. The gels were evaluated for drug content, 
viscosity determination, in vitro permeation and stability studies. The drug content of the gels 
was found to range from 98-105.7 %. The viscosity of the gels ranged between 7100-83144 cps.  
In-vitro diffusion profile of Adapalene gel obtained in ethanol with water (80:20) indicates that 
40.33% drug release found within 6 hrs. While 35.22% of marketed preparation. Although the 
difference is insignificant, the percentage release of drug was found to increase in the following 
orderofthepolymercomposition:  
Carbopol980 > Carbopol940 > Carbopol934 > HPC > SODIUMCMC > HPC+SODIUM CMC     
> METHYL CELLULOSE > HPMC > HPC+HPMC. The best formulation was found to be 
stable at accelerated stability condition. 
Sureewan Duangjit et al., 2010 The goal of this study was developed and evaluate the potential 
use of liposome and Transferosomes vesicles in the transdermal drug delivery of Meloxicam, 
Meloxicam-loaded vesicles were prepared and evaluated for particle size, zeta potential, 
entrapment efficiency, loading efficiency, stability, and in vitro skin permeation. The vesicles 
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were spherical in structure, 90 to 140nm in size, and negatively charged (−23 to −43mV). The % 
Entrapment efficiency of Meloxicam in the vesicles ranged from 40 to 70%. Transferosomes 
provided a significantly higher skin permeation of Meloxicam compared to liposomes. Fourier 
Transform Infrared Spectroscopy and Differential Scanning Calorimetry analysis indicated that 
the application of Transferosomes significantly disrupted the stratum corneum lipid. These 
researches suggest that Meloxicam-loaded Transferosomes can be potentially used as a 
transdermal drug delivery system. 
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CHAPTER-VI 
AIM AND OBJECTIVE OF THE WORK 
 In this world peoples are affected pain problems. Normally they are taken pain killer 
tablets. Those types of tablets produce the intestinal problems. So, I will overcome that problems 
going for niosomal topical delivery. 
Lornoxicam is a non-steroidal anti-inflammatory agent (NSAIDs), has been widely used 
in the treatment of rheumatoid arthritis, osteoarthritis. When it is taken orally it causes side 
effects such as nausea, drowsiness, diarrhea, fast heart beating, ringing in ears, etc. Because of 
these side effects the patient compliance may reduce. The best alternative route for 
administration of Lornoxicam is topical route. 
 However, even though Non-steroidal anti inflammatory drugs are used in the vast skin 
disorders and some side effects. The Lornoxicam main side effect was gastrointestinal bleeding 
and also low half life, poor solubility and high first pass metabolism. 
 To achieve the above aim, niosome is one of the right choices. Since they can entrap both 
hydrophilic and lipophilic drugs, it can be employed as a suitable drug carrier for Non-steroidal 
anti inflammatory drugs.    
 Then various Lornoxicam niosomes were prepared by altering the ratios between various 
non ionic surfactants and same amount of cholesterol by thin film hydration method.  
 The prepared niosomes were subjected to drug content analysis, Entrapment efficiency, 
Invitro drug release studies and Release kinetics of the formulations. The best niosomal 
preparations were formulated as gel. The niosomal gel was evaluated drug content, pH, viscosity, 
transmission electron microscopy. Finally the niosomal gel and plain gel were subjected to 
invitro drug release studies and in vivo animal studies.  
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CHAPTER-VII 
PLAN OF WORK 
The plan of work involves the following steps: 
1) STANDARD CURVE FOR LORNOXICAM 
 Preparation of calibration medium 
 Determination of absorption maximum (λmax) by UV spectrum 
 Calibration curve for Lornoxicam 
2) DRUG –EXCIPIENTS INTERACTION STUDIES 
Fourier Transform-Infrared Spectroscopic Studies (FT-IR) 
Differential Scanning Calorimetry 
3) PREPARATION OF LORNOXICAM LOADED NIOSOMES 
 Preparation of niosomal formulations using various ratios of non ionic surfactants and 
cholesterol by thin film hydration method. 
4) EVALUATION OF NIOSOMAL FORMULATION 
  
 Drug Content Analysis 
 
Estimation of Entrapment Efficiency 
 
Invitro Drug Release Studies  
 
Kinetics of drug release 
 
5) PREPARATION OF NIOSOMAL GEL FORMULATIONS 
 Formulation of the best niosomal formulation in to gel form for topical drug delivery. 
 
6) EVALUATION OF NIOSOMAL GEL FORMULATIONS 
 
Drug content analysis 
 
pH measurements 
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Rheological studies 
 
Transmission electron microscopy 
 
Particle size analysis 
 
In-vitro release studies 
 
Kinetics of drug release 
 
Anti-inflammatory studies 
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CHAPTER - VIII 
 
MATERIALS AND EQUIPMENTS 
 
 
MATERIALS USED:    
Drug- lornoxicam    - Micro lab, Hosur India 
Poly acrylic acid (Carbopol 940)  - Dr. Reddys Lab, Hyderabad 
Cholesterol    - Sis co Research Lab, Mumbai 
Sorbitonmonopalmitate   - S.D.fineChem, Mumbai 
Sorbitonmonostearate   - S.D.fineChem, Mumbai               
Sorbitonmonooleate   - S.D.fineChem, Mumbai                    
Tween-60     - HimediaLab, Mumbai                                
Tween-40     - Himedia Lab, Mumbai 
Tween- 20     - Reachem, Chennai 
Tween- 80     - Himedia Lab, Mumbai 
Chloroform    - HPLC, Mumbai 
Methanol     - Rankem, New Delhi 
n-propanol     - Nice Chemical, Kochi 
Sodium chloride    - Central Drug House, New Delhi 
Potassium dihydrogen ortho phosphate - HPLC, Mumbai 
Disodium hydrogen ortho phosphate - HPLC, Mumbai 
Dialysis memebrane 50 – LA 387 - Himedia Lab, Mumbai 
Brij 52     - Sigma Aldrichco, USA 
Triethanolamine    - S.D.fineChem, Mumbai 
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EQUIPMENTS USED: 
Rotary Flash Evaporator    - Super fit rotary flash evaporator, Mumbai 
Ultra Sonicator    - Vibronic’s Ultrasonic processor 
Electronic Balance   - A&D Company, Japan 
Magnetic Stirrer     - MC Dalal& co, Chennai 
UV Visible Spectrophotometer  - UV Pharma Spec 1700, Shimadzu, Japan 
Cooling Centrifuge Apparatus            - Eppendorf Centrifuge 5417R, Germany 
Particle size analyzer   - Marlven,U.K 
Transmission electron microscopy - Hitachi S-3400, Japan. 
FT-IR Spectrophotometer           - Shimadzu, Japan. 
Differential Scanning Calorimeter - Perkin ElmerSTA 6000, Mumbai.                               
Refrigerator    - Kelvinator, India.  
Environmental chamber   - Inlabequipments (Madras) Pvt. Ltd, 
P
H
 Meter     - Dalal Company, Chennai. 
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CHAPTER-IX 
DRUG PROFILE 
                                                LORNOXICAM [Haberfed, H, 2009]
 
SYNONYM
 
• Chlortenoxicam 
• Lorcam        
• Xefocam 
STRUCTURE    
    
IUPAC NAME      
(3E)-6-Chloro-3-[hydroxyl (pyridine-2-ylamino) methylene]-2-methyl-2, 3-dihydro-
4H-thieno [2, 3-e][1,2]thiazin-4-one 1,1-dioxide. 
CHEMICAL FORMULA
 
                
C13H10ClN3O4S2 
DESCRIPTION  
Nature    :  Yellow crystalline powder 
Solubility   :          Soluble in 0.1N/NAOH,  
       Soluble in chloroform, Insoluble in water 
Melting point   :  225-230°C  
Molecular weight  :           371.81gm/mol 
Log P (octanol/p
H 
7.4 buffer) :  1.8 (Lornoxicam) 
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PKa    : 13.63 (Lornoxicam) 
CATEGORY 
• Non-steroidal anti-inflammatory drug. 
• Antipyretic agent. 
IDENTIFICATION
 
 UV light absorption at 375 nm. 
PHARMACODYNAMIC PROPERTIES
 
Lornoxicam NSAID that is used in musculoskeletal, joint disorders and other painful 
conditions including postoperative pain. Lornoxicam is a potent inhibitor both COX-1 and 
COX-2 enzyme. 
PHARMACOKINETIC PROPERTIES 
Absorption 
• Lornoxicam is absorbed rapidly and almost completely from the gastro-intestinal 
tract. 
• Maximum plasma concentrations are achieved after approximately 1 to 2 hours. 
Metabolism 
Lornoxicam is found in the plasma in unchanged from and as its hydroxylated 
metabolite. The hydroxylated metabolite exhibits no pharmacological activity. CYP2C9 has 
been shown to be the primary enzyme responsible for the biotransformation of the 
lornoxicam its major metabolite, 5-hydroxylornoxicam. Lornoxicam 5-hydroxylation by the 
variant CYP2C9*3 and CYP2C9*13 is markedly reduced compared with wild type, both in 
vivo and in vitro. 
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Excretion  
Excreted in the feces (as metabolites) and urine (as unchanged drug). Mean 
elimination half life of 3-4 hours. 
Pharmacokinetic Characters of Lornoxicam
 
Bioavailability            :  90-100% 
Protein binding           :  99% 
Metabolism                 :            CYP2C9 
Half life                      :  3-4 hours 
Excretion                    :             1/3 Renal, 2/3 Hepatic 
THERAPEUTIC INDICATIONS
 
• Lornoxicam is used for the treatment of various types of pain, especially resulting 
from inflammatory diseases of the joints, osteoarthritis, and other inflammations. 
• Antipyretic agents. 
DOSE
 
Oral 
  Pain relief 8-16 mg daily.maximum:24 mg daily (Adult). Osteoarthritis 12 mg daily in 
2-3 divided doses, up to 16 mg daily if needed.(Adult) 
Parenteral 
8 mg once or twice daily by IM/IV injection. Maximum:24 mg daily (Adult) 
STORAGE 
Protected from light. 
SIDE EFFECTS
 
• Abdominal pain, 
• Diarrhea, 
CHAPTER IX                                                        DRUG PROFILE  
 
71 
 
• Dizziess 
• Dyspepsia 
• Nausea 
• Vomiting 
• Headache 
• Hematologic disorders 
• CNS effects 
• Tinnitus 
• Visual disturbance 
• Fluid retention 
• Stomatitis 
• Hypertension 
DRUG INTERACTIONS
 
• Increased lornoxicam blood concentration when given concomitantly with cimetidine. 
• Enhanced effects of anticoagulants, sulfonylurea, methotrexate, cyclosporine, and 
digoxin.  
• Decreased effects of diuretics, ACE inhibitors 
SPECIAL PRECAUTIONS
 
• Active infections  
• Asthma 
• Allergic disorders 
• hemorrhagic disorders 
• hypertension 
• impaired renal 
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• hepatic 
• cardiac function 
CONTRA INDICATIONS 
• Contraindicated in pregnancy, 
• Contraindicated in lactation, 
• Patients with peptic ulceration,  
• Severe renal impairment. 
BRAND NAMES 
• Lorcam (Taisho Pharmaceutical Co.) 
• Xafon (Nycomed) 
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CHAPTER-X 
                                                EXCIPIENTS PROFILE       
                CHOLESTEROL (Raymond C Rowe et al., 2006) 
SYNONYM 
• Cholesterin, Cholesterolum 
CHEMICAL NAME 
• Cholest -5- en-3β -ol. 
EMPIRICAL FORMULA 
• C17 H46 O 
MOLECULAR WEIGHT 
• 386.67 
FUNCTIONAL CATEGORY 
• Emollient 
• Emulsifying agent 
DESCRIPTION 
• Cholesterol occurs as white or faintly yellow, almost odourless, pearly leaflets, needles, 
powder or granules. 
• On prolonged exposure to light and air, it acquires a yellow to tan color. 
PROPERTIES 
 Boiling Point   360 
o 
C 
 Density   1.052g/cm
3
 for anhydrous form  
 Melting Point                 147-150oC 
Solubility   Soluble in acetone and vegetable oils.  
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Practically insoluble in water and chloroform                                                  
STABILITY AND STORAGE CONDITIONS 
• It is stable, and should be stored in a well-closed container and protected from light. 
SAFETY 
• It is generally regarded as an essentially non-toxic and non-irritant material at the levels 
employed as an excipients. 
HANDLING PRECAUTIONS 
• Rubber or plastic gloves, eye protection and a respirator are recommended. 
METHOD OF MANUFACTURE 
• The commercial material is normally obtained from the spinal cord of cattle by extraction 
with petroleum ether, but it may also be obtained from wool fat. Purification is normally 
accomplished by repeated bromination. Cholesterol may also be produced by entirely 
synthetic means. 
REGULATORY STATUS 
• Induced in the FDA inactive ingredients. 
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                                                           POLYSORBATE 20 
SYNONYM 
• Armotan PML 20, Capmul POE-l, TW 20, T-MAZ-20, Tween 20. 
CHEMICAL NAME 
• Polyoxy ethylene 20 sorbitan mono laurate sorbitan mono decanoate 
EMPIRICAL FORMULA 
• C58H114 O26 
MOLECULAR WEIGHT 
• 1128 
DESCRIPTION 
• It is Yellow oily liquid and having characteristic odour and bitte 
METHOD OF MANUFACTURE 
Polysorbates are prepared from sorbitol in a three-step process. Water is initially removed 
from the sorbitol to form a sorbitan (a cyclic sorbitol anhydride). The sorbitan is then partially 
esterified with a fattyacid such as oleic acid (or) stearic acid to yield a hexiton ester. Finally, 
ethylene oxide is chemically added in the presence of a catalyst to yield the polysorbates. 
PROPERTIES 
 Acid value            2.0 
 Hydroxyl value            96 – 108 
Density (g/cm3)      1.1g/cm3 
 HLB Value      16.7 
 Solubility      Soluble in ethanol and water. Insoluble in mineral oil and 
     vegetable oil.   
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FUNCTIONAL CATEGORY 
• Emulsifying agent 
• Nonionic surfactant 
• Solubilizing agent 
• Wetting agent 
• Useful to improving oral bioavailability of drug molecule 
• Widely used in cosmetics and food products. 
STABILITY 
• Stable to electrolytes and weak acids and bases, Gradual saponification occur with strong 
acids or bases. 
• Hygroscopic 
• Prolonged storage leads to the formation of peroxides. 
STORAGE 
• It should be stored in a well-closed container and protected from light 
SAFETY 
• Widely used in cosmetics, food products, oral, parenteral and topical pharmaceutical 
formulations and generally regarded as non-toxic and non-irritant materials.  
• Daily intake according to the WHO limit is 25mg/Kg body weight. 
• LD50 (rat, oral) is about 37gm/Kg. 
 
HANDLING PRECAUTIONS 
• Eye protection and Gloves are recommended  (Raymond C Rowe et al.,2006) 
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POLYSORBATE 40
 
SYNONYM 
Crillet 2, E434, sorbox PMP, Tween 40. 
CHEMICAL NAME 
Sorbitan monohexa decanoate. 
EMPIRICAL FORMULA 
C62 H122 O26 
MOLECULAR WEIGHT 
1284 
DESCRIPTION 
Yellow oily liquid. 
METHOD OF MANUFACTURE 
Polysorbates are prepared from sorbitol in a three-step process. Water is initially removed 
from the sorbitol to form a sorbitan (a cyclic sorbitol anhydride). The sorbitan is then partially 
esterified with a fattyacid such as oleic acid (or) stearic acid to yield a hexiton ester. Finally, 
ethylene oxide is chemically added in the presence of a catalyst to yield the Polysorbates 
PROPERTIES 
Acid value          2.0 
 Hydroxyl value           90 – 105 
 Saponification value   41 - 52 
 Density (g/cm
3
)     1.08g/cm
3
 
 HLB Value     15.6 
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Solubility  Soluble in ethanol and water. Insoluble in mineral oil and 
Vegetable oil.    
FUNCTIONAL CATEGORY 
• Emulsifying agent 
• Nonionic Surfactant 
• Solubilizing agent 
• Wetting agent 
• Dispersing / suspending agent. 
STABILITY 
• Gradual soap formation occurs with strong acids or bases. 
• Stable in weak acids or bases. 
STORAGE 
 It should be stored in a well-closed container in a cool, dry place. 
SAFETY 
 Daily intake according to the WHO limit is about 25mg/Kg body weight and moderately 
toxic by IV route. 
HANDLING PRECAUTIONS 
 Eye protection and Gloves are recommended. 
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POLYSORBATE 60
 
SYNONYM 
Atlas 70k, Atlas Armotan PMS 20, Glycosporse s-20, Tween 60, Tween 60k, Tween 
60VS. 
CHEMICAL NAME 
Sorbitanmono Octadecanoate. 
EMPIRICAL FORMULA 
C64 H126 O26 
MOLECULAR WEIGHT 
1312 
DESCRIPTION 
Yellow oily liquid.  
METHOD OF MANUFACTURE 
Polysorbates are prepared from sorbitol in a three-step process. Water is initially removed 
from the sorbitol to form a sorbitan (a cyclic sorbitol anhydride). The sorbitan is then partially 
esterified with a fattyacid such as oleic acid (or) stearic acid to yield a hexiton ester. Finally, 
ethylene oxide is chemically added in the presence of a catalyst to yield the polysorbates. 
PROPERTIES 
Acid value            2.0 
 Hydroxyl value            81 – 96 
 Saponification value     45 - 55 
 Density (g/cm
3
)       1.1g/cm
3
 
 HLB Value   14.9 
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 Solubility       Soluble in ethanol and water. Insoluble in mineral oil and  
     Vegetable oil.  
FUNCTIONAL CATEGORY 
• Emulsifying agent 
• Nonionic surfactant 
• Solubilizing agent 
• Wetting agent 
• Dispersing / suspending agent. 
STABILITY 
• Gradual soap formation occurs with strong acids or bases 
• Stable in weak acids or bases. 
STORAGE 
• It should be stored in a well-closed container in a cool, dry place. 
SAFETY 
• Daily intake according to the WHO limit is about 25mg/Kg body weight and moderately 
toxic by IV route. 
HANDLING PRECAUTIONS 
• Eye protection and Gloves are recommended. 
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POLYSORBATE 80
 
SYNONYM 
Atlas E, Capmul POE-o, Glycosporse o-20, Tego SMO 80, Tego SMO 80 x, Tween 80. 
CHEMICAL NAME 
(Z) Sorbitan mono-9- Octadecanoate poly (oxy 1, 2, ethanediyl) derivatives. 
EMPIRICAL FORMULA 
C64 H124 O26 
MOLECULAR WEIGHT 
1310 
DESCRIPTION 
Yellow oily liquid. 
METHOD OF MANUFACTURE 
Polysorbates are prepared from sorbitol in a three-step process. Water is initially removed 
from the sorbitol to form a sorbitan (a cyclic sorbitol anhydride). The sorbitan is then partially 
esterifies with a fatty acid such as oleic acid (or) stearic acid to yield a hexiton ester. Finally, 
ethylene oxide is chemically added in the presence of a catalyst to yield the polysorbates  
PROPERTIES 
Acid value           2.0 
 Hydroxyl value            65 – 80 
 Saponification value    45 - 55 
 Density (g/cm
3
)      1.08g/cm
3
 
 HLB Value   15 
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Solubility      Soluble in ethanol and water. Insoluble in mineral oil and         
     Vegetable oil.         
FUNCTIONAL CATEGORY 
• Emulsifying agent 
• Nonionic surfactant 
• Solubilizing agent 
• Wetting agent 
• Dispersing / suspending agent. 
STABILITY 
• Gradual soap formation occurs with strong acids or bases 
• Stable in weak acids or bases. 
STORAGE 
• It should be stored in a well-closed container in a cool, dry place. 
SAFETY 
• Daily intake according to the WHO limit is about 25mg/Kg body weight  
• LD50 (Mouse, oral)-25g/Kg. 
HANDLING PRECAUTIONS 
• Eye protection and Gloves are recommended. 
REGULATORY STATUS 
Polysorbates 20,40,60,65 and 80 are accepted as food additives in Europe. Polysorbates 
20, 40, 60, and 80 are included in the FDA inactive ingredients guide (IM, IV, Oral, rectal, 
topical and vaginal preparations). Polysorbates are included in parenteral and non-parenteral 
medicines licensed in the UK.  
CHAPTER X                                               EXCIPIENTS PROFILES  
 
83 
 
                                                              CARBOPOL 940  
STRUCTURE 
 
 SYNONYMS 
Acritamer; acrylic acid polymer; Carbopol; carboxypolymethylene,polyacrylic acid; 
carboxyvinyl polymer; Pemulen;Ultrez. Chemical Name and CAS Registry Number 
Carbomer 
EMPIRICAL FORMULA AND MOLECULAR WEIGHT 
Carbomer are synthetic high-molecular-weight polymers of acrylic acid that are cross 
linked with either allyl sucrose or allyl ethers of pentaerythritol. They contain between 56% and 
68% of carboxylic acid (COOH) groups 104 400 g/mol for Carbopol 940 have been reported 
STRUCTURAL FORMULA 
Carbomer polymers are formed from repeating units of acrylic acid. The polymer chains 
are cross linked with allyl sucrose or allyl pentaerythritol. 
FUNCTIONAL CATEGORY 
Bioadhesive; emulsifying agent; release-modifying agent; suspending agent; tablet 
binder; viscosity-increasing agent. 
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APPLICATIONS IN PHARMACEUTICAL FORMULATION OR TECHNOLOGY 
Carbomer are mainly used in liquid or semisolid pharmaceutical formulations as 
suspending or viscosity-increasing agents. Formulations include creams, gels, and ointments for 
use in ophthalmic, (5–7) rectal, (8–10) and topical preparations. 
EMULSIFYING AGENT  
0.1–0.5 
GELLING AGENT  
0.5–2.0 
SUSPENDING AGENT 
0.5–1.0 
TABLET BINDER 
5.0–10.0 
DESCRIPTION 
Carbomer are white-colored, ‘fluffy’, acidic, hygroscopic powders with a slight 
characteristic odor. 
PHARMACOPEIAL SPECIFICATIONS 
Carbomer 940 (0.5 w/v) — 40 000–60 000(a) 
TYPICAL PROPERTIES 
Acidity/alkalinity 
pH = 2.7–3.5 for a 0.5% w/v aqueous dispersion; 
PH = 2.5–3.0 for a 1% w/v aqueous dispersion. 
Density (bulk) 
1.76–2.08 g/cm3 
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Density (tapped)  
1.4 g/cm3 
Glass transition temperature 
100–105ºC 
Melting point 
Decomposition occurs within 30 minutes at 260ºC. 
Moisture content 
  Normal water content is up to 2% w/w.However, Carbomer are hygroscopic and typical 
equilibrium moisture content at 25ºC and 50% relative humidity is 8–10% w/w. The moisture 
content of a Carbomer does not affect its thickening efficiency (Raymond C Rowe et al., 2006). 
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        SORBITAN MONOPALMITATE 
SYNONYMS 
Ablunol S-40, Armotan  MP, Liposorb P, Span 40,  Arlacel 40,  Montane 40,  Sorbitan 
Palmitate. 
CHEMICAL NAME 
Sorbitan monohexa decanoate. 
EMPIRICAL FORMULA 
C22H42 O6 
MOLECULAR WEIGHT 
403 
DESCRIPTION 
It occurs as cream solid with a distinctive odour and taste. 
METHOD OF MANUFACTURE 
Sorbitol is dehydrated to form a hexiton (1,4 Sorbitan) which is then esterified with the 
desired fatty acid. 
PROPERTIES 
Acid value 3 to 7 
Hydroxyl value 270 to 303 
Iodine value ≤ 1 
Density (g/cm
3
) 1.0 
HLB Value 6.7 
Melting point 43
0
C - 48
o
C 
Solubility Soluble in oils and in organic solvents. Insoluble in water. 
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FUNCTIONAL CATEGORY 
• Emulsifying agent. 
• Non ionic Surfactant. 
• Solubilizing agent. 
• Wetting agent. 
STABILITY 
It should be stored in a well-closed container in a cool, dry place. 
SAFETY 
It is generally regarded as non-toxic and non-irritant material. 
HANDLING PRECAUTIONS 
Eye protection and Gloves are recommended (Raymond C Rowe et al., 2006).
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SORBITAN MONOSTEARATE 
SYNONYMS 
Ablunol S-60, Alkamuls SMS, Sorgen 50, Tego SMS, Span 60, Arlacel 60, Durtan 60, 
Montane 60, Sorbitan Stearate. 
CHEMICAL NAME 
Sorbitan mono – Octadecanoate. 
EMPIRICAL FORMULA 
C24 H46 O6 
MOLECULAR WEIGHT  
431 
DESCRIPTION 
It occurs as a cream solid with a distinctive odour and taste. 
METHOD OF MANUFACTURE 
Sorbitol is dehydrated to form a hexiton (1,4 Sorbitan) which is then esterified with the 
desired fatty acid. 
PROPERTIES 
Acid value 5 to 10 
Hydroxyl value 235 to 260 
Iodine value ≤ 1 
HLB Value 4.7 
Melting Point 53
0
C – 57
o
C 
Solubility Soluble in oils and in most organic solvents.  Insoluble 
but dispersible In water. 
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FUNCTIONAL CATEGORY 
• Emulsifying agent. 
• Nonionic Surfactant. 
• Solubilizing agent. 
• Wetting agent. 
STABILITY 
• Gradual Soap formation occurs with strong acids or bases. 
• Stable in weak acids or bases. 
STORAGE 
It should be stored in a well-closed container in a cool, dry place. 
SAFETY 
• It is generally regarded as non-toxic and non-irritant material. 
• Very mildly toxic by ingestion. 
HANDLING PRECAUTIONS 
Eye protection and Gloves are recommended. 
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SOBITAN MONO OLEATE 
SYNONYMS 
Ablunol S-80, Armotan MO, Capmul O, Crill 4, Lames orb SMO, Span 80, Arlacel  80, 
Montane 80, Sorgen 40, Sorbitan Oleate. 
CHEMICAL NAME 
(Z) - Sorbitan mono -9- Octa deaconate. 
EMPIRICAL FORMULA 
C24 H44 O6 
MOLECULAR WEIGHT 
429 
DESCRIPTION 
It occurs as yellow viscous liquid with a distinctive odour and taste. 
METHOD OF MANUFACTURE 
Sorbitol is dehydrated to form a hexiton (1,4 Sorbitan) which is then esterified with the 
desired fatty acid. 
PROPERTIES 
Acid value ≤ 8 
Hydroxyl value 193 to 209 
Pour point 12 
Density (g/cm
3
) 1.01 
HLB Value 4.3 
Solubility Soluble in oil and in most organic solvents. 
Insoluble but dispersible in water. 
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FUNCTIONAL CATEGORY: 
• Emulsifying agent. 
• Nonionic surfactant. 
• Solubilizing agent. 
• Wetting agent. 
STABILITY: 
• Gradual soap formation occurs with strong acids or bases 
• Stable in weak acids or bases. 
STORAGE: 
It should be stored in a well-closed container in a cool, dry place. 
SAFETY: 
It is generally regarded as non-toxic and non-irritant material. 
HANDLING PRECAUTIONS: 
Eye protection and Gloves are recommended (Raymond C Rowe et al., 2006).
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CHAPTER-XI 
EXPERIMENTAL PROTOCOL 
1) STANDARD CURVE FOR LORNOXICAM 
Preparation of calibration medium 
Phosphate buffered saline pH 7.4 
Dissolve 2.38 g of disodium hydrogen phosphate, 0.19 g of potassium dihydrogen 
phosphate and 8.0 g of sodium chloride in sufficient quantity of distilled water and the 
volume made up to1000 ml. 
        Determination of absorption maximum (λmax) by UV spectrum 
UVspectrum is obtained for 10µg/ml concentration of lornoxicam using standard 
buffer solution (Phosphate buffered saline pH 7.4). 
       Calibration curve for Lornoxicam 
 100mg of Lornoxicam is accurately weighed and dissolved in a small quantity of 
methanol and made up to 100ml with the phosphate buffered saline pH 7.4. From this 
primary solution 10ml is pipetted out and made up to 100ml with phosphate buffered saline 
pH 7.4. From this secondary solution aliquots are taken to produce 2, 4, 6, 8, 10, 12, 14, 16, 
18, 20µg/ml. 
 The absorbance of the resulting solution is measured at 375nm in the UV-Visible 
Spectrophotometer (Shimadzu UV-1700 Pharma spec Japan) using phosphate buffered saline 
pH 7.4 as blank ( Metker Vishal et al.,2011). The standard curve is plotted by taking 
concentration in X-axis and Absorbance in Y-axis. 
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2) DRUG –EXCIPIENTS INTERACTION STUDIES 
      Fourier Transform-Infrared Spectroscopic Studies (FT-IR) 
The possibility of drug-excipients (cholesterol, nonionic surfactants) interactions are 
further investigated by FT-IR study. The FT-IR spectrum of pure drug and combination of 
drug with excipient are obtained by using JASCO FT-IR Spectrophotometer. The scanning 
range is 400-4000 cm
-1 
and the resolution is 1cm
-1
(Md.Ismail Mouzan et al., 2010). Samples 
is prepared in KBr pellets (Jasco FT-IR 5300 Japan). 
   Differential Scanning Calorimetry
 
  Thermogram of the pure drug, Cholesterol, non ionic surfactant and physical mixtures 
(drug, surfactants and cholesterol) are obtained using a shimadzu W70 thermal analyzer for 
differential scanning calorimeter. Samples (4-8mg) are sealed into aluminum pans and 
measurements are run from 25º to 300º C against an empty pan (Md.Ismail Mouzan et al., 
2010). 
3) PREPARATION OF LORNOXICAM LOADED NIOSOMES: 
Thin Film Hydration Method
 
 Different ratios of surfactant and cholesterol are used to prepare niosomes with the 
concentration of the drug being the same. 
 The niosome formulations are prepared by thin film hydration technique. The 
weighed amount of cholesterol, non-ionic surfactant dissolved in 5ml of solvent mixture 
(Chloroform: Methanol 2:1 ratio). 20 mg of lornoxicam is dissolved in 20ml of chloroform to 
make clear solution. It is then transferred into a 100ml round bottom flask. A thin film is 
formed under reduced pressure in a rotary flash evaporator rotated at 100rpm at 55ºC. The 
organic solvent is evaporated to form a dry film on the walls of the flask. An appropriate 
amount of phosphate buffered saline pH 7.4 is added slowly to the round bottom flask having 
thin film of surfactant and cholesterol and vortexed continuously for a period of 45 minutes at 
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55ºC, until a good dispersion of the mixture is obtained. The niosomal dispersion is collected 
and stored at 4ºC for maturation (Vijay Prakash Pandey et al., 2009, Vijay S .Jatav et al., 
2011, Vyas Jigar et al., 2011). The empty niosomes also prepared by the same method 
without the drug for further evaluation. 
4) EVALUATION OF NIOSOMAL FORMULATION: 
Drug Content Analysis 
 
 The amount of drug in the formulation is determined after lysing the niosomes using 
50% n- propanol. Niosomes preparation equivalent to 200 µg of Lornoxicam (1ml) is 
pipetted out in 100 ml standard flask. To this sufficient quantity of 50% n- propanol is added 
and shaken well for the complete lyses of the vesicles. The volume is made up to 100 ml with 
the buffer phosphate buffered saline pH 7.4. The absorbance is measured at 375nm in the                    
UV-Visible Spectrophotometer (Shimadzu UV-1700 Pharma spec Japan) using empty 
niosomes as blank. The drug content is calculated from the standard curve, by using the 
following formula,  
		
		 =
	
	

		

	 
Estimation of Entrapment Efficiency 
 Lornoxicam niosome preparations (1 ml) are centrifuged at 14,000 rpm for 120 
minutes at 4ºC using a refrigerated centrifuge (Eppendorf, 5417R, Germany) in order to 
separate niosomes from unentrapped drug (Kandasamy Ruckmani et al., 2010, Meenakshi 
Chauhan et al., 2009). The free drug concentration in supernatant layer after centrifugation is 
determined at 375 nm using UV-Visible Spectrophotometer (Shimadzu UV-1700 Pharma 
spec Japan). The percentage of drug entrapment in niosomes is calculated using the following 
formula, 
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(Total drug – Unentrapped drug) 
   % drug entrapment=                      × 100 
Total drug 
Invitro Drug Release Studies 
Invitro release pattern of niosomes suspension is carried out by dialysis bag (Himedia 
M.W 12000). The niosomal preparation of Lornoxicam is placed in a dialysis bag with an 
effective length of 5 cm which acts as a donor compartment. Dialysis bag is placed in a 
beaker containing 250 ml of buffer phosphate buffered saline pH 7.4, which acts as receptor 
compartment. The temperature of receptor medium maintained at 37±1ºC and the medium is 
agitated at 50 rpm speed using magnetic stirrer. Aliquots of 5 ml samples are collected at 
predetermined time and replenished immediately with the same volume of fresh phosphate 
buffered saline pH 7.4. The sink condition is maintained throughout the experiment. The 
collected samples are analyzed spectrophotometrically at 375 nm using UV-Visible 
Spectrophotometer (ShimadzuUV-1700 Pharma spec Japan). Each study is performed in 
triplicate (Manivannan Rangasamy et al., 2008, Yasmin Begum et al., 2011). The invitro 
release studies are also carried out for the pure drug by same method.
 
Kinetics of drug release 
 
                 
To understand the pharmacokinetics and mechanism of drug release, the result of in-
vitro drug release study of niosomes are fit with various pharmacokinetic equations like zero 
order (cumulative % release vs. time), first order (log % drug remaining vs. time), Higuchi's 
model (cumulative % drug release vs. square root of time), and the korsmeyer-peppas (log 
cumulative % drug release vs. log time) and Hixson- Crowell models (cubic root of drug 
remaining Vs time). The r
 2 
and k values were calculated for the linear curve obtained by 
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regression analysis (Meenakshi Chauhan et al., 2009, Rathi Jagdish Chandra et al., 2009, 
Ibrahim A. Alsarra et al., 2005 Tamizharasi et al., 2009).
  
5) PREPARATION OF NIOSOMAL GEL FORMULATIONS 
Preparation of Lornoxicam niosomal gel 
            Carbopol 940 gel bases are prepared by homogenizing 1 % (w/w) carbopol dispersion 
in sufficient water using a magnetic stirrer for 30 minutes and leaving it to equilibrate for 24 
hours. After that, pH is adjusted to 5 – 7 with Triethanolamine (Saleem M.A, et al., 2010). 
The lornoxicam loaded niosomes is added to the prepared plain gel base during the stirring 
process and the step is completed as mentioned for carbopol plain gel bases. 
6) EVALUATION OF NIOSOMAL GEL FORMULATIONS 
Drug content analysis 
         An accurately weighed quantity of each Lornoxicam niosomal gel (100 mg) is 
dissolved in 50 ml of phosphate buffer (pH 7.4). These solutions are quantitatively 
transferred to volumetric flask and appropriate dilutions are made with the same buffer 
solution. (Fathy I. Abd-Allah et al., 2010). The resulting solutions are then filtered through 
membrane filters (pore size 0.45 mm) before subjecting the solution to spectro photometric 
analysis for Lornoxicam at 375 nm (Shimadzu UV‐VIS spectrophotometer). 
pH measurements 
The pH is measured in each niosomal gel using a pH meter. This is calibrated before 
each use with buffered solutions at pH 4, 7 & 10. 1 gram of gel is taken and diluted with 100 
ml of distilled water and stored for two hours. The electrode of the pH meter is immersed in 
the prepared base solution for pH determination. The pH determination is carried out in 
triplicate and the average reading is recorded (Prabhudutti Panda et al., 2010). 
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Rheological studies 
             The viscosity of gel formulation is carried out on Brook-field viscometer using spindle 
number S-06, and the determinations is carried out in triplicate and the average of three reading is 
recorded (Fathy I. Abd- Allah et al.,2010). 
Transmission electron microscopy 
The morphology of the lornoxicam niosomal gel dispersions are determined by 
transmission electron microscopy. A drop of niosomal gel dispersion is applied to a carbon 
coated 300 – mesh copper grid and left to adhere on the carbon substrate for about 1 min.The 
remaining gel dispersion was removed by a piece of filter paper. A drop of 2% aqueous 
solution of uranyl acetate was applied for 35 seconds and again the solution in excess was 
removed by the tip of filter paper (RitaMuzzalupo et al., 2008, Muzzalupo et al., 2011). The 
sample was air dried and observed under the transmission electron microscope at 90 kV. 
Particle size analysis 
  The vesicle size distribution is determined using a laser technique on a master sizer.      
(X Ver.2.15; Malvern instrunents Ltd. Malvern, UK). The measurements were performed at 
25º C using a 45 mm focus lens and a beam length 2.4 mm (Mohamed Nasr et al., 2009). 
In-vitro release studies 
 
In-vitro release study is carried out by taking 1 g of gel formulations into dialysis bag 
and placed beaker containing 100 ml PBS pH 7.4 at 37 ± 10˚C. The beakers placed over a 
magnetic stirrer and stirred at 50 rpm. Aliquots of samples are withdrawn at specified time 
intervals and analyzed at 375 nm by using an UV spectrophotometer to determine the 
percentage drug released and replaced with equal volume of fresh PBS pH7.4 (A. Abdul 
Hasan Sathali et al., 2010).  
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Kinetics of drug release 
To understand the pharmacokinetics and mechanism of drug release, the result of in-
vitro drug release study of niosomes gel are fit with various pharmacokinetic equations like 
zero order (cumulative % release vs. time), first order (log % drug remaining vs. time), 
Higuchi's model (cumulative % drug release vs. square root of time), and the korsmeyer-
peppas (log cumulative % drug release vs. log time) and Hixson- Crowell models (cubic root 
of drug remaining Vs time). The r
 2 
and k values were calculated for the linear curve obtained 
by regression analysis (Meenakshi Chauhan et al., 2009, Rathi Jagdish Chandra et al., 2009, 
Ibrahim A. Alsarra et al., 2005 Tamizharasi et al., 2009).
 
 
Anti-inflammatory studies 
            The studies were conducted on albino rats of either sex, weighing 150-200g. The 
animals in each were selected so that the average body weight among the groups as close as 
possible. (Ref No 14024/E1/4/2011) . Inflammation is produced in the rats by injecting 0.1ml 
of 1% w/v carrageenam niosomal gel formulations and plain gel (Drug dispersion in 
carbopol) and without drug gel was applied topically on the edematous paw by gently 
rubbing with an index finger.  Topical activities of the various formulations were evaluated 
by measuring an increase in the hind paw thickness with the help of digital plethesmograph.  
Before and after (1, 2, 3, 4, 6, and 24 hours) carrageenam administration.  The percentage of 
paw thickness increase from time 0 were calculated with compared with control group. 
Group-1(Control) 
            Animal were treated with carrageenam 
Group-2 (Standard) 
            Animal were treated with Lornoxicam plain gel. 
Group-3 (Test-1) 
            Animals were treated with Test-1(High entrapment niosomal gel). 
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Group-4 (Test-2) 
            Animal were treated with Test-2(Low entrapment niosomal gel) 
 The percentage inhibitions of paw thickness were calculated by the following formula: 
(Munish Ahuja et al., 2011). 
                          
Percentage inhibition = [C –T / C] × 100 
        Where; 
              C = Control Paw edema 
            T = Test Paw edema  
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CHAPTER-XII 
RESULTS AND DISCUSSION 
1) STANDARD CURVE FOR LORNOXICAM 
Preparation of calibration medium 
The preparation of calibration medium was prepared by using phosphate buffer                       
saline pH 7.4. 
Determination of absorption maximum (λmax) by UV spectrum  
The λ max of Lornoxicam was determined by scanning the 10µg/ml of drug solution in 
phosphate buffered saline (PBS) pH 7.4 at 375 nm in UV visible spectrophotometer (Metker 
Vishal et al., 2010).  The graph was shown in Figure 7 
Calibration curve for Lornoxicam 
Calibration curve of Lornoxicam was plotted by measuring the absorbance of different 
concentrations of the drug in phosphate buffered saline pH at 375 nm in the UV- visible 
spectrophotometer (Shimadzu UV-1700 Pharma spec Japan). The Lornoxicam obeys the Beers 
law within the concentration of 2 to 20 µg/ml. The λ max at UV region of 375 nm. The calibration 
data and graph were shown in Table 3 and Figure 8  
2) DRUG –EXCIPIENTS INTERACTION STUDIES  
Fourier transform- Infra red spectroscopic studies (FT-IR) 
         FT-IR spectrum of pure drug, surfactants, cholesterol and physical mixtures (drug, 
surfactant and cholesterol). From this study it was observed that there was no significant 
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interaction between the pure drug and the physical mixture used in the formulations. (Rathi 
Jagdish Chandra et al., 2009).The results were shown in Figure 9A- I 
Table No: 2 The FT-IR spectra of lornoxicam drug show as follows: 
S. No Wave Number (cm
-1
). Bond 
1. 
2. 
3. 
 
4. 
 
5. 
 
6.  
3090  
1642  
1597, 1559  
 
1157, 1387 and 1336  
 
827.94  
 
766.8  
 
 
NH stretching 
C=O group in the primary amide 
Bending vibrations of the N–H 
group in the secondary amide  
Stretching vibrations of the 
O=S=O  
 
–CH aromatic ring bending and 
heteroaromatics  
 
C–Cl bending vibration 
 
 Differential scanning Calorimetry 
DSC studies are useful method of detecting drug-excipient incompatibility. DSC 
Thermogram of the pure drug (Lornoxicam), Non-ionic surfactants (Span 40, Span 60, Tween 
20, and Tween 40), cholesterol and physical mixtures are shown in the Figure: 10A- I. Drug 
showed the sharp melting endothermic peak at 221.61º C. The non-ionic surfactants Span 40, 
Span 60, Tween 20 and Tween 40 showed the sharp melting endothermic peak at 48º C, 57º C, 
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134ºC and 51.45ºC. The physical mixtures Span60, cholesterol and lornoxicam showed the sharp 
melting endothermic peak at 59.19ºC, the physical mixtures Tween 60, cholesterol and 
lornoxicam showed the sharp melting endothermic peak at 69.79ºC and the physical mixtures 
Tween 80, cholesterol and lornoxicam showed the sharp melting endothermic peak at 83.40ºC. It 
suggests that the formulation components Span 60, Span 40, Tween 20, Tween 40, cholesterol 
and the drug lornoxicam do not interact to form any additional chemical entity but remain as 
mixture. (Md.Ismail Mouzan et al., 2010). 
3) PREPARATION OF LORNOXICAM LOADED NIOSOMES 
In the present study, thirty two  niosomal formulations were prepared by thin film 
hydration method using  different ratios of  non-ionic surfactants (Span 40,60 and 80, Tween 20, 
40, 60, 80 and Brij-52 ) along with Cholesterol(25µmol)  and concentration of the drug(2mg/ml) 
being constant .The formula were shown in Table 4,5 and 6. 
4) EVALUATION OF NIOSOMAL FORMULATION: 
Drug content analysis: 
The percentage drug content of all the formulations (F1 – F32) were found to be range 
95% to 96.95% ensured the uniformity of drug content in all formulations. The results were 
shown in Table 18 
Estimation of Entrapment efficiency  
The entrapment efficiency of the prepared niosomal formulations were measured by 
centrifugation method. The entrapment efficiency was determined by subtracting the amount of 
drug entrapped from the total amount of drug in the formulation. The results of the niosomal 
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formulations maximum entrapment obtained for the formulation containing (F32) Brij-52 and 
cholesterol in the ratio (10:1) was 92.05%. This may be attributed to its length of longer side 
chain (lauryl), and it easily diffuse into receptor membrane integrity, orientation and packaging 
ability of Brij- 52 ( Kumar et al., 2012).  In all the formulation, the impact of surfactants on 
entrapment efficiency was significant. 
Effect of non ionic surfactant on entrapment efficiency 
The entrapment efficiency of niosomal formulations were (Span 40: Cholesterol) 75.86%, 
76.38%, 77.13% and79.26% for formulationsF1 (4:1), F2 (6:1), F3 (8:1) and F4 (10:1) 
respectively and the orders as follows. 
F1 < F2 < F3 < F4 
The entrapment efficiency of niosomal formulations were (Span 60: Cholesterol) 84.38%, 
86.69%, 87.06% and 89.91% for formulations F4 (4:1), F6 (6:1), F7 (8:1) and F8 (10:1) 
respectively and the orders as follows. 
F5 < F6 < F7 < F8 
The entrapment efficiency of niosomal formulations were (Span 80: Cholesterol) 66.75% 
68.48%, 69.51% and 70.27% for formulations F9 (4:1), F10 (6:1), F11 (8:1) and F12 (10:1) 
respectively and the orders as follows. 
F9 < F10 < F11 < F12 
The entrapment efficiency of niosomal formulations were (Tween 20: Cholesterol) 
70.13%, 71.14%, 72.31% and 73.37% for formulations F13 (4:1), F14 (6:1), F15 (8:1) and F16 
(10:1) respectively and the orders as follows. 
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F13 < F14 < F15 < F16 
The entrapment efficiency of niosomal formulations were (Tween 40: Cholesterol) 
74.03%, 75.37%, 77.28% and 79.23% for formulations F17 (4:1), F18 (6:1), F19 (8:1) and F20 
(10:1) respectively and the orders as follows. 
F17 < F18 < F19 < F20 
The entrapment efficiency of niosomal formulations were (Tween 60: Cholesterol) 
86.69%, 87.44%, 88.72% and 89.48% for formulations F21 (4:1), F22 (6:1), F23 (8:1) and F24  
(10:1) respectively and the orders as follows. 
F21 < F22 < F23 < F24 
The entrapment efficiency of niosomal formulations were (Tween 80: Cholesterol) 
67.65%, 69.51%, 70.55% and 71.24% for formulations F25 (4:1), F26 (6:1), F27 (8:1) and F28 
(10:1) respectively and the orders as follows. 
F25 < F26 < F27 < F28 
The entrapment efficiency of niosomal formulations were (Brij 52: Cholesterol) 88.19%, 
89.21%, 90.25% and 92.05% for formulations F29 (4:1), F30 (6:1), F31 (8:1) and F32 (10:1) 
respectively and the orders as follows. 
F29 < F30 < F31 < F32 
From the above results it was observed that increase in the concentration of non ionic 
surfactant, increased the entrapment efficiency of niosomes formulations. (A. Abdul Hasan 
Sathali et al., 2010). 
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 These results explained that the brij-52 has higher entrapment efficiency than other span 
series and Tween series .This could be due to variation in the surfactant chemical structure. 
Increasing the alkyl chain length is leading to higher entrapment efficiency. The entrapment 
efficiency followed the trend Brij-52 > Sp 60 > Tween 60 > Tween 40 > Sp 40 > Tween 20 > 
Tween 80 > Sp 80. Among the all surfactants Span 80 showed low entrapment efficiency due to 
introduction of double bonds into the paraffin chains. Addition, niosome loaded with lornoxicam 
confirming the hypothesis that entrapment efficiency may be correlated with the hydrophobicity 
of the alkyl chain (Kumar et al., 2012). The results were shown in Table  7, 8 and 9. The result 
was shown in Figure 11. 
 Invitro Drug Release studies 
The invitro release study of Lornoxicam loaded niosomes by dialysis bag method using 
phosphate buffered saline (PBS) pH7.4.  
The Lornoxicam pure drug solution showed invitro release of 98.33% within 5 hours. 
The invitro release of Lornoxicam loaded niosomes was slower and controlled than the 
Lornoxicam pure drug solution (0.2mg/ml).  
The cumulative percentage release of niosomal formulations were (Span 40: Cholesterol) 
95.63%, 87.56%, 79.30% and 72.70% for formulations F1 (4:1), F2 (6:1) F3 (8:1) and F4 (10:1) 
at 12 hours respectively.  
F1> F2 > F3 > F4 
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The cumulative percentage release of niosomal formulations were (Span 60: Cholesterol) 
77.46%, 71.27%, 63.27% and 57.19% for formulations F5 (4:1), F6 (6:1), F7 (8:1) and F8 (10:1) 
at 12 hours respectively. 
F5 > F6 > F7 > F8 
The cumulative percentage release of niosomal formulations were (Span 80: Cholesterol) 
94.4%, 90.9%, 85.7% and 74.30% for formulations F9 (4:1), F10 (6:1), F11 (8:1) and F12 (10:1) 
at 12 hours respectively. 
F9 > F10 > F11 > F12 
The cumulative percentage release of niosomal formulations were (Tween 20: 
Cholesterol) 97.8%, 86.9%, 80.0% and 61.5% for formulations F13 (4:1), F14 (6:1), F15 (8:1) 
and F16 (10:1) at 12 hours respectively. 
F13 > F14 > F15 > F16 
The cumulative percentage release of niosomal formulations were (Tween 40: 
Cholesterol) 98.0%, 84.8%, 82.15% and 67.4% for formulations F17 (4:1), F18 (6:1), F19 (8:1) 
and F20 (10:1) at 12 hours respectively. 
F17 > F18 > F19 > F20 
The cumulative percentage release of niosomal formulations were (Tween 60: 
Cholesterol) 90.20%, 86.10%, 81.40% and 76.0% for formulations F21 (4:1), F22 (6:1), F23 
(8:1) and F24 (10:1) at 12 hours respectively, 
F21> F22 > F23 > F24 
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The cumulative percentage release of niosomal formulations were (Tween 80: 
Cholesterol) 89.50%, 85.81%, 77.58% and 72.33% for formulations F25 (4:1), F26 (6:1), F27 
(8:1) and F28 (10:1) at 12 hours respectively. 
F25 > F26 > F27 > F28 
The cumulative percentage release of niosomal formulations were (Brij 52: Cholesterol) 
87.54%, 77.44%, 75.99% and 68.97% for formulations F29 (4:1), F30 (6:1), F31 (8:1) and F32 
(10:1) at 12 hours respectively. 
F29 > F30 > F31 > F32 
From the above results, it was showed that increase in surfactant concentration, decreased 
the drug release. Important changes in release were observed upon changing the nature of the 
surfactant used in the Lornoxicam loaded niosomes. The experimental studies of niosomal 
formulations showed that the rate of drug release depends on the percentage of drug entrapment 
efficiency (Manivannan Rangasamy et al 2008). The results were shown in Table 10, 11, 12, 
13,14,15,16 and 17. The result was shown in Figure 12A-H 
Effect of surfactant concentration in invitro drug release 
 Increase the molar ratio of nonionic surfactant in niosomes controlled the drug release 
from niosomal vesicles. The  presence of high molar ratio  of non-ionic surfactant in  F8(10:1), 
F16(10:1), F20(10:1), F32(10:1), F28(10:1), F4(10:1), F12(10:1) , F24(10:1) and  exhibit  the 
maximum  drug release after  12 hrs about  57.19%, 61.5%, 67.47%, 68.97%, 72.33%,72.7%       
74.30%, 76.0% and respectively. These similar results were shown in (Kandasamy Ruckmani et 
al., 2010). 
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F8 < F16 < F20 < F32 < F28 < F4 < F12 < F24 
This is might be due to the high concentration of surfactant in the formulations. The 
hydrophilic surfactant having more HLB values may be the reason for more hydrophilic and high 
swelling of vesicles and higher release of drug after 12 hours than the other surfactant containing 
niosomes. The entire amount of loaded drug was not released from the niosomes. This is may be 
due to entrapment of the drug in the lipophilic region. The release also depends of alkyl chin 
length of the surfactant. (Kumar et al., 2012).The result was shown in Figure 13. 
Kinetics of drug release 
Linear regression analysis for the release was done to determine the proper order of drug 
release. All the formulations follow zero order kinetics. Calculation of Higuchi correlation 
coefficient confirms that the drug release was proportional to the square root of time indicating 
that lornoxicam release from niosomes was diffusion controlled. The formulation F1, F9, F10, 
F13, F17, and F21 was followed Higuchi model. The n value from the Korsmeyer- Peppas model 
for lornoxicam niosomal formulation were  between 0.681 - 0.999  which indicated the 
formulations F2, F3, F4, F5, F6, F7, F11, F12, F14, F15, F18, F19, F20, F22, F23, F25, F28,F29, 
F30 and F31 followed the Non-Fickian mechanism. The formulations F8, F24, F26, F27 and F32 
followed the super case II mechanism. (Kandasamy Ruckmani et al., 2010, Y.Anand Kumar et 
al., 2010). The results were shown in Table 19, 20, 21 and 22 Figure 14A-E. 
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5) PREPARATION OF NIOSOMAL GEL FORMULATIONS 
Preparation of Lornoxicam niosomal gel 
 The selected  niosomal formulation  F8(Span 60:Cholesterol)(10:1) and F24(Tween 
60:Cholesterol)(10:1) (on the basis of entrapment efficiency ,in vitro drug release) was 
incorporated in to suitable gel base (carbopol940) 1% to obtain 0.02% of the drug and plain 
Lornoxicam gel was prepared by incorporating the drug in to suitable gel base to obtain same 
0.02% of the drug. The results were shown in Table 23.     
6) EVALUATION OF NIOSOMAL GEL FORMULATIONS 
Drug Content analysis 
The percentage drug content of all the formulations (FG1, FG2 and FG3) were found to 
be 95.4%, 96.2% and 95% ensured the uniformity of drug content in all formulations. The results 
were shown in Table 24. 
pH measurements 
The formulationFG1, FG2 and FG3 were smooth and homogeneous appearance. They 
were easily spreadable with acceptable. The pH values ofFG1, FG2 and FG3 formulations ph 
6.8. This is considered acceptable to avoid the risk of irritation upon application to the skin. The 
results were shown in Table 25. 
Rheological Studies 
A viscometer (Brookfield+ II LV viscometer) was used to measure the viscosities (in cps) 
of the gels. The spindle (TF 64) was rotated at 0.5 rpm upto 100 rpm. Samples of the gels were 
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to settle over 30 min at the assay temperature (28 ±/1ºC) before the measurements were taken. 
The viscosity of FG2 gel was found to be 20000 cps in0.5 rpm.The viscosity of FG3 gel was 
found to be 19500 cps in 0.5 rpm (Japan Patel et al., 2011). The results were shown in Table 26. 
Transmission electron microscopy 
Results of transmission electron microscopic (TEM) study of niosomal gel prepared from 
FG2 and FG3 formulations were shown in Figures. Most of the vesicles were well identified, 
spherical and discrete with sharp boundaries having large internal aqueous space.         
(A.Mansroi et al., 2008).The results were shown in Figure 15A-D. 
Particle size analysis 
        The particle size analysis of the lornoxicam loaded niosomal gel FG2 (131 nm) and         
FG3 (137 nm). The obtained low value of polydispersity index lornoxicam loaded niosomal gel 
indicated a limited variation in particle size. (P.Loan Honeywell- Nguyen et al., 2002)(Mohamed 
Nasr et al., 2009).The results were shown in Figure 16A and16B. 
In-vitro release studies 
 In vitro release studies were performed for the niosomal gel by dialysis bag method. The 
cumulative percentage drug release of formulation containing (FG1) lornoxicam plain gel 
showed 95.68% at 12 hours.  The cumulative percentage drug release of formulation containing 
(FG2) span 60 niosomal gel showed 69.92% at 12 hours.  The cumulative percentage drug 
release of formulation containing (FG3) niosomal gel showed 85.57% at 12 hours. The results 
showed prolonged drug release in the order FG2 > FG3 > FG1. (Kandasamy Ruckmani et al., 
2010).  The results were shown in Table 27 and Figure 17. 
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Kinetics of drug release       
          Linear regression analysis for the release was done to determine the proper order of drug 
release. All the formulations follow zero order kinetics. Calculation of Higuchi correlation 
coefficient confirms that the drugs release was proportional to the square root of time indicating 
that lornoxicam release from niosomal gel was diffusion controlled. The formulations FG1 
(0.9957), FG2 (0.9805), FG3 (0.9964) were followed the Higuchi diffusion controlled model 
(Tamizharasi Sengodan et al., 2009).The results were shown in Table 28 Figure 18. 
Anti- inflammatory studies 
The anti-inflammatory studies were performed in albino rats by rat hind paw oedema 
method.  
     The percentage reduction in paw oedema of lornoxicam plain gel was found to be 
39.64% up to 24 hour. The percentage reductions in paw oedema of formulations                   
(FG2-Span 60), (FG3-Tween 60) were found to be 22.36% and 40.11% upto 24 hour 
respectively. From the above results, (FG2) span 60 niosomal gel showed sustained as well as 
prolonged action when compared with the Lornoxicam plain gel (FG1) and Tween 60 niosomal 
gel (FG3). 
The formulation (FG2) Span 60 niosomal gel showed sustained release due to slower 
diffusion of drug into the skin and creation of reservoir effect for drug in the skin. The other 
components of niosomes (surfactant, cholesterol) also deposit along with drug into the skin and 
thereby increasing the drug retention capacity into skin (Munish Ahuja et al., 2011). The results 
were shown in Table 29 and Figure 19.                                                                          
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CHAPTER- XIII 
SUMMARY AND CONCLUSION 
• The λ max of Lornoxicam was found to be 375nm in phosphate buffer saline (PBS)    
pH 7.4. 
• The Lornoxicam obeys the Beers law within the concentration of 2 to 20 µg/ml. 
• DSC and FT-IR studies indicated that there was no interaction between drug and 
excipients. 
• Lornoxicam niosomes were prepared using different ratios of non-ionic surfactants 
with cholesterol and same concentration of drug by thin film hydration method. 
• The niosomal formulations were evaluated for drug content, entrapment efficiency, 
invitro release studies and kinetic drug release. 
• The percentage drug content of all the formulations was found to be in the range of 
95% to 96.95%. 
• The entrapment efficiency was found to be higher for niosomal formulation F32 when 
compared to other niosomal formulations due to the length of alkyl chain of Brij 52. 
• The invitro release study showed prolonged release profile for all the thirty two 
niosomal formulations compared to the pure drug solution. The formulation F24 
showed highest drug release at 12
th
 hour. The formulation F8 showed controlled drug 
release at 12
th 
hour. 
• On the basis of entrapment efficiency and invitro release study, the niosomal 
formulation (F8) and (F24) equivalent to 0.02% w/w of lornoxicam was incorporated 
into carbopol gel base and evaluated with 1% w/w of plain lornoxicam gel. The gels 
were easy to prepare and found to be homogenous in composition. 
• The niosomal gels were evaluated for drug content. 
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• The pH and viscosity of the gel formulation were also evaluated. 
• The Transmission electron microscopy showed spherical and discrete vesicles with 
sharp boundaries having large internal aqueous phase. 
• The particle size evaluated for niosomal gels FG2 and FG3 were found to be 131 nm 
and 137 nm. 
• The invitro release studies of lornoxicam niosomal gel formulations exposed that the 
release rate of lornoxicam niosomal gel(FG2) was slower than that of plain 
lornoxicam gel(FG1) and Tween 60 niosomal gel(FG3). 
• The invitro release kinetics also evaluated that all niosomal formulations obeys the 
Higuchi diffusion model. 
• The anti-inflammatory activity of lornoxicam niosomal gel (FG2) showed uniform 
and prolonged activity when compared to the plain gel (FG1) and Tween 60 niosomal 
gel (FG3). Therefore the present study suggests the potentiality of niosomal gel to 
enhance the therapeutic effect and minimize the side effects of lornoxicam. 
• From the above study it is concluded that the niosomes can be considered as 
promising drug delivery vehicles which increase the duration of the drugs. Thus 
niosomes help in formulating dosage forms having more prolonged action. 
• The niosomal delivery of lornoxicam in carbopol gel base acts as a suitable topical 
drug delivery system which may be given safely to all patients suffering from 
rheumatoid arthritis and osteoarthritis. The stability of niosomes improved after 
incorporation into gel base may be due to prevention of fusion of niosomes. Further 
the pharmacokinetic and other clinical studies may be carried out in future. 
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Figure.8 STANDARD CURVE OF LORNOXICAM IN PBS pH 7.4 
 
 
 
A) LORNOXICAM 
 
 
B) LORNOXICAM AND CARBOPOL 
 
 
 
C) LORNOXICAM, TWEEN 20 AND CHOLESTEROL 
 
D) LORNOXICAM, TWEEN 40 AND CHOLESTEROL 
 
 
 
E) LORNOXICAM, TWEEN 60 AND CHOLESTEROL 
 
 
F) LORNOXICAM, TWEEN 80 AND CHOLESTEROL 
 
 
G) LORNOXICAM, SPAN 40 AND CHOLESTEROL 
 
 
H) LORNOXICAM, SPAN 60 AND CHOLESTEROL 
 
 
I) LORNOXICAM, SPAN 80 AND CHOLESTEROL 
 
 
Figure.9 FT-IR SPECTRUM ARE AS FOLLOWS: A) LORNOXICAM,                       
B) LORNOXICAM AND CARBOPOL, C) LORNOXICAM, TWEEN 20 AND 
CHOLESTEROL, D) LORNOXICAM, TWEEN 40 AND CHOLESTEROL,                
E) LORNOXICAM, TWEEN 60 AND CHOLESTEROL, F) LORNOXICAM, TWEEN 
80 AND CHOLESTEROL, G) LORNOXICAM, SPAN 40 AND CHOLESTEROL, H) 
LORNOXICAM, SPAN 60 AND CHOLESTEROL, I) LORNOXICAM, SPAN 80 AND 
CHOLESTEROL 
 
 
 
 
 
 
      A) CHOLESTEROL 
      B) SPAN-60 
 
 
C) SPAN- 40 
 
D) TWEEN 20
              E) TWEEN 40
 
 
F) LORNOXICAM 
 
 
G) SPAN 60 LORNOXICAM CHOLESTEROL 
 
H) TWEEN 60 CHOLESTEROL LORNOXICAM 
 
 
I) TWEEN 80 CHOLESTEROL LORNOXICAM 
 
FIGURE 10 DSC THERMOGRAM ARE AS FOLLOWS:  
A) CHOLESTEROL B) SPAN-60 C) SPAN-40 D) TWEEN-20                          
E) TWEEN-40 F) LORNOXICAM G) SPAN-60 , CHOLESTEROL 
AND LORNOXICAM H) TWEEN-60, CHOLESTEROL AND 
LORNOXICAM I) TWEEN-80, CHOLESTEROL  AND 
LORNOXICAM 
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Figure.12A COMPARISON OF INVITRO RELEASE OF LORNOXICAM NIOSOMES CONTAINING SPAN 40 AT 
DIFFERENT RATIOS 
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Figure.12B COMPARISON OF INVITRO RELEASE OF LORNOXICAM NIOSOMES CONTAINING SPAN 60 AT 
DIFFERENT RATIOS 
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Figure.12C COMPARISON OF INVITRO RELEASE OF LORNOXICAM NIOSOMES CONTAINING SPAN 80 AT 
DIFFERENT RATIOS 
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Figure.12D COMPARISON OF INVITRO RELEASE OF LORNOXICAM NIOSOMES CONTAINING TWEEN 20 AT 
DIFFERENT RATIOS 
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Figure.12E COMPARISON OF INVITRO RELEASE OF LORNOXICAM NIOSOMES CONTAINING TWEEN 40 AT 
DIFFERENT RATIOS 
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Figure.12F COMPARISON OF INVITRO RELEASE OF LORNOXICAM NIOSOMES CONTAINING TWEEN 60 AT 
DIFFERENT RATIOS 
 
 
 
 
TIME IN HOURS
C
U
M
U
L
A
T
I
V
E
 
%
D
R
U
G
 
R
E
L
E
A
S
E
0 1 2 3 4 5 6 7 8 9 10 11 12 13
0
10
20
30
40
50
60
70
80
90
100
110
F25  TWEEN 80 (4:1)
F26  TWEEN 80 (6:1)
F27  TWEEN 80 (8:1)
F28  TWEEN 80 (10:1)
PURE DRUG SOLUTION
 
 
Figure.12G COMPARISON OF INVITRO RELEASE OF LORNOXICAM NIOSOMES CONTAINING TWEEN 80 AT 
DIFFERENT RATIOS 
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Figure.12H COMPARISON OF INVITRO RELEASE OF LORNOXICAM NIOSOMES CONTAINING BRIJ 52 AT 
DIFFERENT RATIOS 
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Figure.13 COMPARISON OF INVITRO RELEASE OF LORNOXICAM NIOSOMES CONTAINING DIFFERENT 
SURFACTANTS AT 10:1 RATIOS 
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Figure.11 COMPARISON OF PERCENTAGE ENTRAPPMENT EFFICIENCIES OF FORMULATIONS CONTAINING 
DIFFERENT NON-IONIC SURFACTANTS 
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B) FIRST ORDER 
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C) HIGUCHI RELEASE KINETICS 
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  Figure.14 COMPARISON OF INVITRO RELEASE KINETICS OF  
FORMULATIONS F8 (SPAN 60), F24 (TWEEN 60) AND F32                      
(BRIJ 52) AS FOLLOWS A) ZERO ORDER B) FIRST ORDER                          
C) HIGUCHI RELEASE KINETICS D) KORSMEYER PEPPAS 
MODEL E) HIXON CROWEL 
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Figure.15A TEM IMAGE OF NIOSOMAL GEL FORMULATIONS (FG 2) 
 
 
 
 
 
 
 
 
  
Figure.15B TEM IMAGE OF NIOSOMAL GEL FORMULATIONS (FG2) 
 
 
 
 
 
 
 
 
 
  
Figure.15C TEM IMAGE OF NIOSOMAL GEL  FORMULATIONS (FG3) 
 
 
 
 
 
 
 
 
 
  
Figure.15D TEM IMAGE OF NIOSOMAL GEL  FORMULATIONS (FG3) 
 
  
Figure.16A PARTICLE SIZE DISTRIBUTION  OF FG2 
 
  
Figure.16B PARTICLE SIZE DISTRIBUTION OF FG3 
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Figure.17 COMPARISON OF INVITRO RELEASE OF LORNOXICAM PLAIN GEL – FG1 AND 
LORNOXICAM NIOSOMAL GEL FG2 AND FG3  
 
A) ZERO ORDER 
 
 
 
 
B) FIRST ORDER 
 
 
 
y = 6.7768x - 14.824
R² = 0.9925
-20
-10
0
10
20
30
40
50
60
70
80
0 2 4 6 8 10 12 14C
U
M
U
L
A
T
IV
E
 %
 D
R
U
G
 R
E
L
E
A
S
E
TIME IN HOURS
y = -0.0438x + 2.1037
R² = 0.9377
0
0.5
1
1.5
2
2.5
0 2 4 6 8 10 12 14
L
O
G
 C
U
M
 D
R
U
G
 R
E
M
A
IN
IN
G
TIME IN HOURS
C) HIGUCHI RELEASE KINETICS 
 
 
 
 
D) KORESEMEYER PEPPAS MODEL 
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Figure.18 COMPARISON OF IN VITRO RELEASE KINETICS OF SPAN 60 
LORNOXICAM NIOSOMAL GEL (FG2) 
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Figure.19 COMPARISON OF PERCENTAGE INHIBITION OF RAT PAW EDEMA USING PLAIN 
LORNOXICAM GEL – FG1 AND LORNOXICAM NIOSOMALGEL FG2 AND FG3.  
 
TABLE. 3 CALIBRATION CURVE OF LORNOXICAM IN                                             
PHOSPHATE BUFFERED SALINE pH 7.4 
 
S.No. 
CONCENTRATION 
(µg/ml) 
ABSORBANCE ± SD* 
1. 2 0.096 ± 0.019 
2. 4 0.187 ± 0.026 
3. 6 0.273 ± 0.016 
4. 8 0.341 ± 0.007 
5. 10 0.408 ± 0.003 
6. 12 0.494 ± 0.002 
7. 14 0.584 ± 0.007 
8. 16 0.659 ± 0.004 
9. 18 0.732 ± 0.026 
10. 20 0.843 ± 0.013 
 
          n = 3*                                                                                         γ = 0.99908 
 
 
 
 
 
 
 
 
 
TABLE. 4 FORMULATIONS OF LORNOXICAM NIOSOMES 
 
 
S.NO 
 
FORMULATION 
 
SURFACTANT 
RATIO OF 
SURFACTANT CHOLESTEROL 
 
1. 
 
F1 
 
SPAN 40 
 
4 
 
1 
 
2. 
 
F2 
 
SPAN 40 
 
6 
 
1 
 
3. 
 
F3 
 
SPAN 40 
 
8 
 
1 
 
4. 
 
F4 
 
SPAN 40 
 
10 
 
1 
 
5. 
 
F5 
 
SPAN 60 
 
4 
 
1 
 
6. 
 
F6 
 
SPAN 60 
 
6 
 
1 
 
7. 
 
F7 
 
SPAN 60 
 
8 
 
1 
 
8. 
 
F8 
 
SPAN 60 
 
10 
 
1 
 
9. 
 
F9 
 
SPAN 80 
 
4 
 
1 
 
10. 
 
F10 
 
SPAN 80 
 
6 
 
1 
 
Drug concentration used in each formulation kept as constant 20mg/10ml. 
In ratio 1 stands for 25µmol.       
 
 
 
TABLE . 5 FORMULATION OF LORNOXICAM NIOSOMES 
 
 
S.NO 
 
FORMULATION 
 
SURFACTANT 
RATIO OF 
SURFACTANT CHOLESTEROL 
 
1. 
 
F11 
 
SPAN 80 
 
8 
 
1 
 
2. 
 
F12 
 
SPAN 80 
 
10 
 
1 
 
3. 
 
F13 
 
TWEEN 20 
 
4 
 
1 
 
4. 
 
F14 
 
TWEEN 20 
 
6 
 
1 
 
5. 
 
F15 
 
TWEEN 20 
 
8 
 
1 
 
6. 
 
F16 
 
TWEEN 20 
 
10 
 
1 
 
7. 
 
F17 
 
TWEEN 40 
 
4 
 
1 
 
8. 
 
F18 
 
TWEEN 40 
 
6 
 
1 
 
9. 
 
F19 
 
TWEEN 40 
 
8 
 
1 
 
10. 
 
F20 
 
TWEEN 40 
 
10 
 
1 
 
11. 
 
F21 
 
TWEEN 60 
 
4 
 
1 
 
Drug concentration used in each formulation kept as constant 20mg/10ml. 
In ratio 1 stands for 25µmol.       
TABLE . 6 FORMULATION OF LORNOXICAM NIOSOMES 
 
 
S.NO 
 
FORMULATION 
 
SURFACTANT 
RATIO OF 
SURFACTANT CHOLESTEROL 
 
1. 
 
F22 
 
TWEEN 60 
 
6 
 
1 
 
2. 
 
F23 
 
TWEEN 60 
 
8 
 
1 
 
3. 
 
F24 
 
TWEEN 60 
 
10 
 
1 
 
4. 
 
F25 
 
TWEEN 80 
 
4 
 
1 
 
5. 
 
F26 
 
TWEEN 80 
 
6 
 
1 
 
6. 
 
F27 
 
TWEEN 80 
 
8 
 
1 
 
7. 
 
F28 
 
TWEEN 80 
 
10 
 
1 
 
8. 
 
F29 
 
BRIJ 52 
 
4 
 
1 
 
9. 
 
F30 
 
BRIJ 52 
 
6 
 
1 
 
10. 
 
F31 
 
BRIJ 52 
 
8 
 
1 
 
11. 
 
F32 
 
BRIJ 52 
 
10 
 
1 
 
Drug concentration used in each formulation kept as constant 20mg/10ml. 
In ratio 1 stands for 25µmol.       
TABLE . 7 % ENTRAPMENT EFFICIENCY OF DIFFERENT FORMULATIONS 
 
S.NO FORMULATION SURFACTANT 
RATIO 
% 
ENTRAPMENT 
SURFACTANT CHOLESTEROL 
 
1. 
 
F1 
 
SPAN 40 
 
4 
 
1 
 
75.86 
 
2. 
 
F2 
 
 
SPAN 40 
 
6 
 
1 
 
76.38 
 
3. 
 
F3 
 
SPAN 40 
 
8 
 
1 
 
77.13 
 
4. 
 
F4 
 
SPAN 40 
 
10 
 
1 
 
79.26 
 
5. 
 
F5 
 
 
SPAN 60 
 
4 
 
1 
 
84.38 
 
6. 
 
F6 
 
SPAN 60 
 
6 
 
1 
 
86.69 
 
7. 
 
F7 
 
SPAN 60 
 
8 
 
1 
 
87.06 
 
8. 
 
F8 
 
SPAN 60 
 
10 
 
1 
 
89.91 
 
9. 
 
F9 
 
SPAN 80 
 
4 
 
1 
 
66.75 
 
10. 
 
F10 
 
SPAN 80 
 
6 
 
1 
 
68.48 
 
 
 
 
 
 
TABLE. 8 % ENTRAPMENT EFFICIENCY OF DIFFERENT FORMULATIONS 
 
S.NO FORMULATION SURFACTANT 
RATIO 
% 
ENTRAPMENT 
SURFACTANT CHOLESTEROL 
 
1. 
 
F11 
 
SPAN 80 
 
8 
 
1 
 
69.51 
 
2. 
 
F12 
 
 
SPAN 80 
 
10 
 
1 
 
70.27 
 
3. 
 
F13 
 
TWEEN 20 
 
4 
 
1 
 
70.13 
 
4. 
 
F14 
 
TWEEN 20 
 
6 
 
1 
 
71.14 
 
5. 
 
F15 
 
 
TWEEN 20 
 
8 
 
1 
 
72.31 
 
6. 
 
F16 
 
TWEEN 20 
 
10 
 
1 
 
73.77 
 
7. 
 
F17 
 
TWEEN 40 
 
4 
 
1 
 
74.03 
 
8. 
 
F18 
 
TWEEN 40 
 
6 
 
1 
 
75.37 
 
9. 
 
F19 
 
TWEEN 40 
 
8 
 
1 
 
77.28 
 
10. 
 
F20 
 
TWEEN 40 
 
10 
 
1 
 
79.23 
 
11. 
 
F21 
 
TWEEN 60 
 
4 
 
1 
 
86.69 
 
 
TABLE . 9 % ENTRAPMENT EFFICIENCY OF DIFFERENT FORMULATIONS 
 
S.NO FORMULATION SURFACTANT 
RATIO 
% 
ENTRAPMENT 
SURFACTANT CHOLESTEROL 
 
1. 
 
F22 
 
TWEEN 60 
 
6 
 
1 
 
87.44 
 
2. 
 
F23 
 
 
TWEEN 60 
 
8 
 
1 
 
88.72 
 
3. 
 
F24 
 
TWEEN 60 
 
10 
 
1 
 
89.48 
 
4. 
 
F25 
 
TWEEN 80 
 
4 
 
1 
 
67.75 
 
5. 
 
F26 
 
 
TWEEN 80 
 
6 
 
1 
 
69.51 
 
6. 
 
F27 
 
TWEEN 80 
 
8 
 
1 
 
70.55 
 
7. 
 
F28 
 
TWEEN 80 
 
10 
 
1 
 
71.24 
 
8. 
 
F29 
 
BRIJ 52 
 
4 
 
1 
 
88.19 
 
9. 
 
F30 
 
BRIJ 52 
 
6 
 
1 
 
89.21 
 
10. 
 
F31 
 
BRIJ 52 
 
8 
 
1 
 
90.25 
 
11. 
 
F32 
 
BRIJ 52 
 
10 
 
1 
 
92.05 
 
 
TABLE . 10 COMPARISON OF INVITRO RELEASE PROFILE OF LORNOXICAM 
NIOSOMES 
 
TIME IN 
HOURS 
 
CUMULATIVE % DRUG RELEASE  ±  SD* 
F1 (SPAN 40 4:1) F2 (SPAN 40 6:1) F3 (SPAN 40 8:1) F4 (SPAN 40 10:1) 
0.25 
7.73 ±0.49 5.06 ±0.33 3.20 ±0.49 1.60 ±0.24 
0.5 
9.30 ±1.32 7.05 ±0.34 5.23 ±0.52 3.29 ±0.23 
0.75 
12.00 ±0.54 9.39 ±0.35 7.60 ±0.79 4.88 ±0.16 
1.0 
16.56 ±0.57 11.76 ±0.29 10.03 ±0.57 6.84 ±0.17 
1.5 
18.32 ±0.59 14.30 ±0.31 12.50 ±0.59 9.33 ±0.18 
2.0 
20.92 ±0.62 16.47 ±0.41 14.70 ±0.61 12.02 ±0.19 
2.5 
23.22 ±0.64 18.65 ±0.34 17.30 ±0.81 14.83 ±0.28 
3.0 
25.99 ±0.67 21.44 ±0.35 21.10 ±0.66 18.41 ±0.29 
3.5 
31.04 ±0.69 24.06 ±0.45 23.80 ±0.63 21.25 ±0.31 
4.0 
32.97 ±0.71 27.03 ±0.47 26.50 ±0.73 24.16 ±0.23 
4.5 
35.66 ±0.24 29.84 ±0.47 29.00 ±0.84 25.63 ±0.32 
5.0 
37.88 ±0.33 32.73 ±0.41 31.90 ±0.80 28.42 ±0.34 
5.5 
40.55 ±0.30 35.71 ±0.51 34.30 ±0.82 30.27 ±0.26 
6.0 
43.02 ±0.33 38.78 ±0.51 36.90 ±0.92 37.10 ±0.36 
6.5 
46.54 ±0.33 41.93 ±0.46 40.50 ±0.86 39.80 ±0.29 
7.0 
51.50 ±0.37 45.17 ±0.56 43.20 ±0.90 42.30 ±0.29 
7.5 
56.61 ±0.37 48.76 ±0.57 46.00 ±0.92 46.80 ±0.02 
8.0 
59.29 ±0.42 52.66 ±0.59 48.80 ±1.02 48.90 ±0.03 
8.5 
63.50 ±0.42 57.46 ±0.61 52.40 ±0.98 51.70 ±0.03 
9.0 
68.31 ±0.51 61.41 ±0.63 57.00 ±1.00 54.95 ±0.04 
9.5 
73.08 ±0.47 65.20 ±0.63 58.70 ±1.33 57.39 ±0.05 
10.0 
78.17 ±0.52 70.61 ±0.66 62.20 ±1.13 60.11 ±0.06 
10.5 
83.67 ±0.54 74.64 ±0.66 67.50 ±1.07 63.83 ±0.07 
11.0 
89.45 ±0.72 79.03 ±0.68 71.80 ±0.39 66.65 ±0.16 
11.5 
91.84 ±0.66 83.19 ±0.71 75.30 ±1.13 69.65 ±0.17 
12.0 
95.63 ±0.51 87.56 ±0.72 79.30 ±1.15 72.70 ±0.19 
n = 3*   
TABLE . 11 COMPARISON OF INVITRO RELEASE PROFILE OF LORNOXICAM 
NIOSOMES 
 
TIME 
IN 
HOURS 
 
CUMULATIVE % DRUG RELEASE  ±  SD* 
F5 (SPAN 60 4:1) F6 (SPAN 60 6:1) F7 (SPAN 60 8:1) F8 (SPAN 60 10:1) 
0.25 
7.70 ±0.49 6.26 ±0.60 2.06 ±0.40 1.23 ±0.25 
0.5 
9.58 ±0.52 7.58 ±0.63 3.37 ±0.42 2.52 ±0.26 
0.75 
12.94 ±0.54 8.84 ±0.51 5.03 ±0.44 3.28 ±0.38 
1.0 
15.55 ±0.57 10.58 ±0.73 6.77 ±0.46 4.54 ±0.04 
1.5 
18.25 ±0.59 12.52 ±0.71 8.31 ±0.44 5.98 ±0.29 
2.0 
21.32 ±0.57 14.57 ±0.74 10.69 ±0.45 7.75 ±0.30 
2.5 
23.97 ±0.64 16.69 ±0.77 12.36 ±0.47 9.60 ±0.31 
3.0 
26.48 ±0.67 18.63 ±0.86 14.40 ±0.19 11.52 ±0.33 
3.5 
29.26 ±0.69 20.65 ±0.84 16.01 ±0.49 13.22 ±0.34 
4.0 
31.82 ±0.87 21.98 ±0.87 18.17 ±0.51 15.27 ±0.35 
4.5 
34.66 ±0.75 24.79 ±0.90 19.67 ±0.57 16.90 ±0.36 
5.0 
36.61 ±0.88 26.70 ±0.98 21.44 ±0.59 18.32 ±0.38 
5.5 
39.32 ±0.80 28.20 ±1.01 23.27 ±0.61 20.30 ±0.39 
6.0 42.44 ±0.83 30.49 ±0.99 25.11 ±0.58 22.59 ±0.40 
6.5 
45.74 ±0.85 32.24 ±1.53 28.26 ±0.65 25.88 ±0.56 
7.0 
48.63 ±0.90 35.69 ±1.08 31.29 ±0.67 27.69 ±0.23 
7.5 
51.68 ±0.90 37.99 ±0.90 34.43 ±0.69 29.87 ±0.60 
8.0 
54.41 ±0.93 41.14 ±1.18 37.59 ±0.66 32.62 ±0.75 
8.5 
57.18 ±0.95 44.29 ±1.16 40.42 ±0.68 35.71 ±0.90 
9.0 
60.21 ±0.98 46.99 ±1.24 43.33 ±0.70 38.77 ±0.78 
9.5 
63.39 ±1.00 49.78 ±1.22 45.58 ±0.76 41.52 ±0.59 
10.0 
66.34 ±1.03 53.11 ±1.30 48.83 ±0.74 44.44 ±0.83 
10.5 
69.04 ±1.05 57.49 ±1.34 53.40 ±0.80 47.33 ±0.81 
11.0 
71.88 ±1.08 62.07 ±1.32 57.32 ±0.81 50.73 ±1.12 
11.5 
74.65 ±1.10 65.76 ±1.40 60.35 ±0.93 54.02 ±0.85 
12.0 
77.46 ±1.13 71.27 ±1.38 63.27 ±0.95 57.19 ±0.81 
 
n = 3*   
TABLE. 12 COMPARISON OF INVITRO RELEASE PROFILE OF LORNOXICAM 
NIOSOMES 
 
TIME 
IN 
HOURS 
 
CUMULATIVE % DRUG RELEASE  ±  SD* 
F9 (SPAN 80 4:1) F10 (SPAN 80 6:1) F11 (SPAN 80 8:1) F12 (SPAN 80 10:1) 
0.25 
6.20 ±0.32 5.20 ±0.48 4.60 ±0.66 3.80 ±0.24 
0.5 
8.20±0.35 9.50 ±0.52 6.30 ±0.25 5.50 ±0.17 
0.75 
10.40±0.37 13.10 ±0.54 8.10 ±0.18 7.30 ±0.26 
1.0 
12.80±0.29 16.50 ±0.57 10.30 ±0.19 9.40 ±0.19 
1.5 
15.40 ±0.31 19.80 ±0.59 11.40 ±0.55 11.60 ±0.20 
2.0 
18.30 ±0.41 23.20 ±1.97 15.90 ±0.29 13.80 ±0.37 
2.5 
21.10 ±0.43 26.50 ±1.54 18.30 ±0.20 16.98 ±0.22 
3.0 
24.00 ±0.35 30.50 ±2.35 22.10 ±0.24 19.60 ±0.23 
3.5 
27.70 ±0.44 33.40 ±1.68 24.60 ±0.34 22.90 ±0.24 
4.0 
34.00 ±0.46 36.70 ±1.59 27.30 ±0.26 26.14 ±0.33 
4.5 
36.70 ±0.40 40.40 ±2.26 29.70 ±0.36 28.40 ±0.34 
5.0 
39.90 ±0.49 43.30 ±1.83 31.60 ±0.29 31.08 ±0.29 
5.5 
43.40 ±0.50 45.80 ±1.67 34.60 ±0.29 33.70 ±0.36 
6.0 
46.50 ±0.44 49.20 ±1.54 37.80 ±0.17 36.50 ±0.29 
6.5 
48.90 ±0.53 51.40 ±1.16 43.10 ±0.25 39.80 ±0.30 
7.0 
52.20 ±0.56 54.20 ±0.85 46.10 ±0.68 42.80 ±0.39 
7.5 
56.10 ±0.58 56.80 ±0.87 50.70 ±0.30 45.50 ±0.40 
8.0 
59.70 ±0.50 59.60 ±0.93 54.30 ±0.32 48.60 ±0.33 
8.5 
63.90 ±0.52 62.40 ±0.72 57.70 ±0.26 51.70 ±0.42 
9.0 
69.50 ±0.62 65.70 ±1.07 61.40 ±0.35 55.50 ±0.44 
9.5 
73.80 ±0.64 70.40 ±0.91 66.50 ±0.36 58.80 ±0.36 
10.0 
78.20 ±0.65 76.10 ±0.70 70.10 ±0.30 61.90 ±0.41 
10.5 
82.70 ±0.70 82.90 ±0.51 74.40 ±0.31 64.90 ±0.38 
11.0 
86.50 ±0.69 84.56 ±0.51 78.10 ±0.41 67.90 ±0.39 
11.5 
90.40 ±0.69 86.40 ±0.52 82.20 ±0.34 71.50 ±0.48 
12.0 
94.40 ±0.63 90.90 ±0.49 85.70 ±0.43 74.30 ±0.41 
n = 3*   
TABLE. 13 COMPARISON OF INVITRO RELEASE PROFILE OF LORNOXICAM 
NIOSOMES 
 
TIME 
IN 
HOURS 
 
CUMULATIVE % DRUG RELEASE  ±  SD* 
F13 (TWEEN 20 
4:1) 
F14 (TWEEN 20 
6:1) 
F15 (TWEEN 20 
8:1) 
F16 (TWEEN 20 
10:1) 
0.25 
4.60 ±0.57 3.70 ±0.33 2.20 ±0.16 1.20 ±0.16 
0.5 
6.50 ±0.44 5.30 ±0.34 4.20 ±0.25 2.40 ±0.19 
0.75 
8.40 ±0.70 7.10 ±0.37 6.40 ±0.26 4.30 ±0.16 
1.0 
10.50 ±0.83 9.20 ±0.29 8.40 ±0.31 5.70 ±0.17 
1.5 
13.00 ±0.61 10.10 ±0.40 15.50 ±0.22 7.50 ±0.27 
2.0 
16.90 ±1.73 14.70 ±0.41 12.70 ±0.30 9.41 ±0.20 
2.5 
21.70 ±2.21 17.40 ±0.44 15.30 ±0.37 11.00 ±0.29 
3.0 
24.50 ±2.11 21.00 ±0.45 17.90 ±0.32 12.90 ±0.30 
3.5 
28.10 ±2.50 24.40 ±0.41 20.70 ±0.33 15.00 ±0.23 
4.0 
31.30 ±2.39 26.90 ±0.18 23.50 ±0.37 17.40 ±0.32 
4.5 
34.90 ±2.03 28.90 ±0.13 26.20 ±0.29 19.40 ±0.25 
5.0 
39.80 ±2.83 31.50 ±0.45 29.50 ±0.39 21.60 ±0.34 
5.5 
43.61 ±2.53 34.70 ±0.75 32.70 ±1.44 24.90 ±0.43 
6.0 
47.93 ±2.04 39.90 ±1.95 37.70 ±0.49 26.70 ±0.21 
6.5 
51.00 ±1.73 45.50 ±0.88 40.90 ±0.41 28.90 ±0.47 
7.0 
55.20 ±1.84 48.90 ±1.28 44.70 ±0.36 31.70 ±0.68 
7.5 
59.80 ±1.99 52.60 ±0.45 48.30 ±0.43 34.80 ±0.80 
8.0 
63.50 ±2.07 55.80 ±0.56 52.00 ±0.44 37.80 ±0.66 
8.5 
67.60 ±1.81 59.50 ±0.67 56.10 ±0.39 40.60 ±0.50 
9.0 
71.80 ±0.98 64.20 ±1.26 60.30 ±0.40 43.30 ±0.65 
9.5 
75.50 ±1.28 68.20 ±0.66 64.60 ±0.36 46.30 ±0.72 
10.0 
79.20 ±1.30 72.40 ±0.87 68.50 ±0.40 49.80 ±0.92 
10.5 
83.20 ±1.50 76.30 ±0.67 72.10 ±0.42 53.10 ±0.71 
11.0 
87.70 ±1.56 80.20 ±0.82 76.10 ±0.43 56.20 ±0.74 
11.5 
92.80 ±1.36 83.70 ±0.35 79.60 ±0.41 59.10 ±0.41 
12.0 
97.80 ±1.25 86.90 ±0.20 80.00 ±0.43 61.50 ±0.99 
n = 3*   
TABLE . 14 COMPARISON OF INVITRO RELEASE PROFILE OF LORNOXICAM 
NIOSOMES 
 
TIME 
IN 
HOURS 
 
CUMULATIVE % DRUG RELEASE  ±  SD* 
F17 (TWEEN 40 
4:1) 
F18 (TWEEN 40 
6:1) 
F19 (TWEEN 40 
8:1) 
F20 (TWEEN 40 
10:1) 
0.25 
5.93±0.33 3.26±0.33 1.73±0.49 0.86±0.33 
0.5 
8.23±0.35 4.96±0.34  3.83±0.45 2.57±0.26 
0.75 
10.16±0.28 6.67±0.37 5.96±0.54 3.77±0.14 
1.0 
14.56±0.37 8.78±0.38 7.96±0.64 6.61±0.36 
1.5 
16.23±0.38 10.38±0.40 10.10±0.58 8.93±0.38 
2.0 
18.69±0.41 14.31±0.33 12.26±0.62 11.34±0.39 
2.5 
27.03±0.34 16.95±0.34 14.83±0.64 13.85±0.41 
3.0 
23.28±0.68 20.42±0.44 17.50±0.67 16.20±0.41 
3.5 
28.25±0.69 22.64±0.53 20.33±0.69 18.63±0.35 
4.0 
30.22±0.71 25.32±0.63 23.06±0.72 23.89±0.44 
4.5 
34.92±1.13 27.62±0.56 25.66±0.73 26.57±0.90 
5.0 
39.02±1.05 29.53±0.56 29.05±0.84 30.74±0.40 
5.5 
41.79±1.16 32.46±0.58 33.06±0.78 33.50±0.67 
6.0 
44.36±1.17 35.88±0.60 37.36±0.81 37.53±0.43 
6.5 
47.91±1.10 41.75±0.50 40.32±0.84 39.72±0.53 
7.0 
53.09±1.20 45.51±0.58 45.16±1.66 42.01±0.55 
7.5 
58.24±1.16 50.38±0.60 47.75±0.89 44.68±0.50 
8.0 
61.03±1.23 53.24±0.62 51.26±1.07 46.87±0.56 
8.5 
65.31±1.24 56.84±0.56 55.43±0.95 49.49±0.58 
9.0 
70.31±1.26 60.84±0.67 59.69±0.96 52.09±0.52 
9.5 
75.11±1.22 65.58±0.70 63.87±0.99 54.81±0.53 
10.0 
80.31±1.29 70.01±0.49 67.73±1.02 57.11±0.63 
10.5 
85.80±1.36 73.54±0.62 71.29±1.04 59.90±0.65 
11.0 
89.85±1.32 77.18±0.70 75.30±1.07 62.75±0.67 
11.5 
94.19±1.24 81.35±0.65 78.73±1.10 65.34±0.67 
12.0 
98.00±1.26 84.80±0.75 82.15±1.12 67.40±0.70 
n = 3*   
TABLE. 15 COMPARISON OF INVITRO RELEASE PROFILE OF LORNOXICAM 
NIOSOMES 
 
TIME 
IN 
HOURS 
 
CUMULATIVE % DRUG RELEASE  ±  SD* 
F21 (TWEEN 60 
4:1) 
F22 (TWEEN 60 
6:1) 
F23 (TWEEN 60 
8:1) 
F24 (TWEEN 60 
10:1) 
0.25 
8.00 ±0.52 4.60 ±0.52 1.93 ±0.64 1.06 ±0.41 
0.5 
10.13 ±0.58 6.20 ±0.52 3.46 ±0.58 2.06 ±0.41 
0.75 
11.63 ±0.25 8.06 ±0.56 5.96 ±0.55 4.16 ±0.41 
1.0 
14.60 ±0.62 10.13 ±0.61 8.36 ±0.40 6.36 ±0.51 
1.5 
16.83 ±0.58 11.10 ±0.62 10.13 ±0.47 8.40 ±0.50 
2.0 
19.63 ±1.10 14.46 ±2.77 12.03 ±0.56 10.53 ±0.40 
2.5 
23.60 ±0.70 18.60 ±0.79 15.26 ±0.68 12.80 ±0.44 
3.0 
25.60 ±0.70 22.03 ±0.51 17.96 ±0.68 15.33 ±0.56 
3.5 
28.06 ±0.73 24.43 ±0.68 21.93 ±0.73 17.96 ±0.58 
4.0 
30.16 ±0.73 27.23 ±0.68 24.86 ±0.77 20.73 ±0.56 
4.5 
32.56 ±0.76 29.56 ±0.68 27.90 ±0.79 23.53 ±0.60 
5.0 
35.40 ±0.79 31.50 ±0.73 31.03 ±0.83 26.26 ±0.51 
5.5 
38.06 ±0.83 34.36 ±0.79 34.00 ±0.81 29.73 ±0.90 
6.0 
41.43 ±0.85 37.60 ±0.76 37.30 ±0.81 32.70 ±1.57 
6.5 
44.20 ±0.81 43.23 ±0.45 40.80 ±0.85 37.86 ±0.55 
7.0 
49.03 ±0.77 46.66 ±0.80 45.50 ±0.88 40.90 ±0.65 
7.5 
52.20 ±0.88 51.00 ±0.80 48.80 ±0.88 44.63 ±0.70 
8.0 
55.53 ±1.13 54.53 ±0.88 52.16 ±0.94 47.26 ±0.70 
8.5 
58.63 ±0.94 57.96 ±0.90 55.40 ±0.98 49.96 ±0.70 
9.0 
62.03 ±1.11 61.73 ±0.92 59.43 ±0.97 53.70 ±0.75 
9.5 
65.20 ±1.01 66.66 ±0.94 63.16 ±1.04 57.63 ±0.64 
10.0 
68.20 ±2.74 70.43 ±0.96 66.33 ±0.98 62.06 ±0.90 
10.5 
75.20 ±1.31 74.73 ±1.04 70.43 ±1.09 66.36 ±0.75 
11.0 
80.03 ±1.04 78.33 ±1.04 73.76 ±0.60 70.13 ±0.86 
11.5 
84.40 ±1.15 82.56 ±1.04 77.90 ±1.24 73.23 ±0.86 
12.0 
90.20 ±1.17 86.10 ±1.15 81.40 ±1.15 76.00 ±0.75 
n = 3*   
TABLE. 16 COMPARISON OF INVITRO RELEASE PROFILE OF LORNOXICAM 
NIOSOMES 
TIME 
IN 
HOURS 
 
CUMULATIVE % DRUG RELEASE  ±  SD* 
F25 (TWEEN 80 
4:1) 
F26 (TWEEN 80 
6:1) 
F27 (TWEEN 80 
8:1) 
F28 (TWEEN 80 
10:1) 
0.25 
4.10 ±0.65 3.08 ±0.37 1.58 ±0.37 1.42 ±0.37 
0.5 5.53 ±0.63 4.72 ±0.39 3.65 ±0.39 3.15 ±0.53 
0.75 7.30 ±0.66 6.41 ±0.37 5.07 ±0.41 4.79 ±0.32 
1.0 9.64 ±0.69 8.31 ±0.55 6.06 ±0.43 6.84 ±0.43 
1.5 11.78 ±0.72 9.35 ±0.44 8.08 ±0.45 9.40 ±0.45 
2.0 14.58 ±0.80 13.95 ±0.49 10.18 ±0.47 12.02 ±0.42 
2.5 18.22 ±0.84 16.57 ±0.51 12.29 ±0.47 14.77 ±0.51 
3.0 
21.74 ±0.82 20.02 ±0.49 14.99 ±0.37 18.43 ±0.53 
3.5 
25.13 ±0.90 24.08 ±0.51 17.47 ±0.50 21.23 ±0.55 
4.0 
28.18 ±0.93 26.37 ±0.57 20.20 ±0.52 24.10 ±0.53 
4.5 
31.57 ±0.91 28.19 ±0.55 23.04 ±0.54 25.60 ±0.55 
5.0 34.53 ±0.94 31.07 ±0.61 25.67 ±0.55 28.35 ±0.61 
5.5 38.14 ±1.03 34.51 ±0.59 28.96 ±0.61 30.23 ±0.59 
6.0 40.77 ±0.50 40.63 ±0.77 33.09 ±0.64 37.08 ±0.60 
6.5 44.62 ±1.06 44.09 ±0.63 37.31 ±0.61 39.68 ±0.77 
7.0 48.19 ±1.04 48.78 ±0.80 40.24 ±0.63 42.24 ±0.69 
7.5 51.92 ±1.07 52.02 ±0.72 44.01 ±0.69 46.79 ±0.71 
8.0 56.02 ±1.16 55.40 ±0.74 47.60 ±0.66 48.95 ±0.69 
8.5 
59.96 ±1.19 59.09 ±0.71 51.28 ±0.69 51.67 ±0.71 
9.0 
63.94 ±1.17 64.09 ±0.77 55.36 ±0.75 54.44 ±0.72 
9.5 
67.58 ±1.20 67.78 ±0.79 59.52 ±0.72 57.26 ±0.74 
10.0 
72.33 ±0.99 72.05 ±0.81 63.76 ±0.74 60.13 ±0.776 
10.5 77.51 ±1.07 75.64 ±0.79 67.68 ±0.80 63.79 ±0.82 
11.0 81.80 ±1.22 79.80 ±0.80 71.42 ±0.82 66.56 ±0.80 
11.5 
85.54 ±1.17 82.78 ±0.83 74.46 ±0.80 69.61 ±0.82 
12.0 
89.50 ±1.01 85.81 ±0.85 77.58 ±0.86 72.33 ±0.91 
 
n = 3*   
 
TABLE . 17 COMPARISON OF INVITRO RELEASE PROFILE OF LORNOXICAM 
NIOSOMES 
 
TIME 
IN 
HOURS 
 
CUMULATIVE % DRUG RELEASE  ±  SD* 
F29 (BRIJ 52 4:1) F30 (BRIJ 52 6:1) F31 (BRIJ 52 8:1) F32 (BRIJ 52 10:1) 
0.25 
6.90 ±0.50 5.76 ±0.40 4.60 ±0.36 2.53 ±0.35 
0.5 
8.74 ±0.52 7.35 ±0.28 6.96 ±0.30 4.29 ±0.26 
0.75 
10.66 ±0.55 8.64 ±0.18 9.40 ±0.43 5.60 ±0.43 
1.0 
13.16 ±0.57 9.80 ±0.13 10.50 ±0.19 6.86 ±0.43 
1.5 
14.95 ±0.60 11.14 ±0.26 12.05 ±0.31 8.57 ±0.29 
2.0 
17.11 ±0.62 12.83 ±0.24 13.21 ±0.21 9.96 ±0.31 
2.5 
19.64 ±0.65 14.54 ±0.43 15.70 ±0.20 11.56 ±0.17 
3.0 
22.16 ±0.67 16.24 ±0.30 18.42 ±0.12 14.08 ±0.17 
3.5 
27.06 ±0.70 18.29 ±0.46 21.28 ±0.13 16.11 ±0.29 
4.0 
30.03 ±0.89 20.62 ±0.33 24.02 ±0.15 17.61 ±0.21 
4.5 
34.06 ±0.68 22.93 ±0.35 27.97 ±0.15 19.05 ±0.19 
5.0 
38.10 ±0.71 25.84 ±0.22 30.65 ±0.16 21.46 ±0.37 
5.5 
41.38 ±0.73 28.76 ±0.41 34.80 ±0.41 25.48 ±0.39 
6.0 
44.94 ±0.76 31.01 ±0.41 38.47 ±0.32 28.84 ±0.16 
6.5 
47.81 ±0.78 33.44 ±0.39 41.09 ±0.11 32.34 ±0.36 
7.0 
51.73 ±0.81 36.21 ±0.72 43.33 ±0.07 35.53 ±0.27 
7.5 
54.87 ±0.83 40.90 ±0.43 46.15 ±0.20 38.99 ±0.17 
8.0 
58.77 ±0.86 44.35 ±0.44 48.82 ±0.21 42.35 ±0.24 
8.5 
63.47 ±0.62 48.23 ±0.64 51.95 ±0.21 44.78 ±0.43 
9.0 
67.50 ±0.42 51.93 ±0.52 55.19 ±0.27 47.85 ±0.16 
9.5 
70.97 ±0.43 55.94 ±0.57 58.73 ±0.22 51.00 ±0.08 
10.0 
74.46 ±0.46 62.15 ±0.49 62.73 ±0.42 54.75 ±0.29 
10.5 
77.71 ±0.55 65.95 ±0.45 66.30 ±0.85 58.81 ±0.55 
11.0 
80.84 ±0.53 68.90 ±0.51 69.35 ±0.16 62.28 ±0.33 
11.5 
83.91 ±0.72 73.06 ±0.54 72.31 ±0.28 65.69 ±0.50 
12.0 
87.54 ±1.81 77.44 ±0.54 75.99 ±0.29 68.97 ±0.50 
n = 3*   
TABLE . 27 COMPARISION OF IN VITRO RELEASE OF VARIOUS GEL 
FORMUATIONS (FG1, FG2 & FG3) 
TIME(MIN) 
CUMULATIVE % DRUG RELEASE OF  
GELS ± S.D* 
FG1 FG2 FG3 
0.25 -4.03±1.92 -9.1 ±2.5 -7.4±2.62 
0.50 -1.00±1.95 -11.13 ±2.01 -4.84±2.37 
0.75 1.49±2.68 -8.35 ±2.49 -1.86±2.03 
1.0 4.48±1.58 -6.24 ±2.83 1.49±1.52 
1.5 6.78±3.00 -2.40 ±2.96 5.32±1.90 
2.0 10.01±1.75 0.31 ±2.41 7.69±1.85 
2.5 13.06±2.04 2.64 ±2.50 10.57±2.49 
3.0 16.90±2.13 5.34 ±1.95 13.16±2.99 
3.5 20.98±2.94 8.57 ±1.77 17.51±3.56 
4.0 25.23±2.80 10.71 ±2.34 20.39±3.83 
4.5 29.64±2.83 14.17 ±1.96 23.79±3.50 
5.0 33.81±2.20 17.36 ±2.05 27.32±3.06 
5.5 37.29±2.78 19.85 ±2.85 30.55±3.17 
6.0 41.32±2.30 22.83 ±3.37 34.72±3.43 
6.5 45.83±3.48 25.92 ±3.52 38.61±3.96 
7.0 50.10±3.60 29.53 ±3.72 43.46±2.18 
7.5 54.08±3.06 34.09 ±3.38 47.23±3.75 
8.0 57.74±3.28 37.57 ±3.75 50.70±2.87 
8.5 62.32±2.90 41.15 ±2.51 55.89±2.98 
9.0 67.03±3.03 45.26 ±2.10 59.60±2.54 
9.5 71.85±3.31 49.07 ±2.85 63.81±2.77 
10.0 76.39±3.28 53.82 ±2.73 68.12±2.85 
10.5 81.45±2.98 57.88 ±3.56 72.54±2.30 
11.0 87.04±2.75 63.29 ±2.43 77.05±2.17 
11.5 91.13±3.34 66.38 ±3.38 81.68±2.15 
12.0 95.68±3.53 69.92 ±2.53 85.57±2.77 
 
n = 3*   
TABLE . 18 COMPARISON OF DRUG CONTENT, % ENTRAPPMENT EFFICIENCY 
& IN VITRO RELEASE PROFILE OF 6
th
 & 12
th
 HOURS IN DIFFERENT NON-IONIC 
SURFACTANT CONCENTRATIONS 
 
F:NO 
DRUG 
%CONTENT 
%ENTRAPPMENT 
EFFICIENCY 
IN VITRO RELEASE 
6
TH
HOUR 12
TH
 HOUR 
F1 95.0 75.86 43.02% 95.63% 
F2 95.7 76.38 38.78% 87.56% 
F3 95.5 77.13 36.90% 79.30% 
F4 96.95 79.26 37.10% 72.70% 
F5 95.5 84.38 42.44% 77.46% 
F6 95.7 86.69 30.49% 71.27% 
F7 95.0 87.06 25.11% 63.27% 
F8 96.95 89.91 22.59% 57.19% 
F9 95.5 66.75 46.5% 94.4% 
F10 96.95 68.48 49.2% 90.9% 
F11 95.0 69.51 37.80% 85.70% 
F12 95.7 70.27 36.50% 74.30% 
F13 96.95 70.13 47.93% 97.80% 
F14 95.0 71.14 39.99% 86.90% 
F15 95.5 72.31 37.7% 80.00% 
F16 95.7 73.77 26.7% 61.50% 
F17 95.7 74.03 44.3% 98.00% 
F18 95.3 75.37 35.8% 84.80% 
F19 95.5 77.28 37.3% 82.15% 
F20 95.0 79.23 37.5% 67.40% 
F21 96.95 86.69 41.43% 90.20% 
F22 95.0 87.44 37.60% 86.10% 
F23 95.7 88.72 37.30% 81.40% 
F24 95.5 89.48 32.70% 76.00% 
F25 95.7 67.65 40.77% 89.50% 
F26 95.0 69.51 40.63% 85.81% 
F27 96.95 70.55 33.09% 77.58% 
F28 95.5 71.24 37.08% 72.33% 
F29 95.7 88.19 44.94% 87.54% 
F30 95.0 89.21 31.01% 77.44% 
F31 95.5 90.25 38.47% 75.99% 
F32 96.95 92.05 28.84% 68.97% 
 
TABLE. 19 DETERMINATION OF ORDER OF RELEASE OF LORNOXICAM FROM NIOSOMAL FORMULATIONS 
 
 
 
Formulation 
 
 
Higuchi 
 
 
Korsemeyer-
Peppas 
 
 
Zero order 
 
First order 
 
Hixon-Crowell 
Release 
Mechanism 
r
2
 
 
KH            
(mg
-h1/2
) 
 
r
2
 n r
2
 
K0 
(% mg/h) 
r
2
 K1 (h
-1
) r
2
 Slope (n) 
F1 0.924 29.31 0.958 0.765 0.987 7.240 0.809 -0.084 0.898 -0.206 HIGUCHI 
F2 0.922 27.30 0.972 0.855 0.988 6.755 0.881 -0.061 0.931 -0.167 NFD 
F3 0.945 25.10 0.988 0.861 0.995 6.154 0.930 -0.049 0.961 -0.140 NFD 
F4 0.957 24.85 0.996 0.983 0.988 6.062 0.969 -0.044 0.985 -0.130 NFD 
F5 0.967 23.69 0.983 0.681 0.998 5.751 0.966 -0.047 0.985 -0.135 NFD 
F6 0.908 20.46 0.963 0.782 0.980 5.079 0.914 -0.036 0.942 -0.108 NFD 
F7 0.913 20.13 0.977 0.936 0.984 4.993 0.939 -0.032 0.957 -0.101 NFD 
F8 0.913 18.54 0.999 1.052 0.999 4.602 0.95 -0.028 0.964 -0.089 
SUPER 
CASE II 
 
 
 
TABLE. 20 DETERMINATION OF ORDER OF RELEASE OF LORNOXICAM FROM NIOSOMAL FORMULATIONS 
      
 
Formulation 
 
 
Higuchi 
 
Korsemeyer-
Peppas 
 
Zero order 
 
First order 
 
Hixon-Crowell 
Release 
Mechanism 
r2 KH (mg
-h1/2) r2 n r2 
K0 (% mg/h) 
r2 K1 (h
-1) r2 Slope (n) 
 
F9 0.944 30.12 0.986 0.854 0.996 7.391 0.854 -0.080 0.930 -0.203 HIGUCHI 
F10 0.965 27.91 0.986 0.704 0.993 6.765 0.894 -0.07 0.949 -0.181 HIGUCHI 
F11 0.932 27.66 0.984 0.907 0.993 6.820 0.906 -0.060 0.948 -0.166 NFD 
F12 0.953 24.25 0.992 0.877 0.998 5.929 0.959 -0.045 0.979 -0.131 NFD 
F13 0.951 31.94 0.995 0.933 0.998 7.817 0.789 -0.093 0.914 -0.223 HIGUCHI 
F14 0.937 29.06 0.988 0.974 0.995 7.154 0.912 -0.064 0.954 -0.176 NFD 
F15 0.930 27.37 0.966 0.942 0.991 6.751 0.928 -0.055 0.958 -0.158 NFD 
F16 0.928 20.29 0.988 1.007 0.992 5.060 0.957 -0.032 0.972 -0.101 NFD 
 
 
 
 
 
TABLE. 21 DETERMINATION OF ORDER OF RELEASE OF LORNOXICAM FROM NIOSOMAL FORMULATIONS 
 
 
Formulation 
 
 
Higuchi 
 
Korsemeyer-
Peppas 
 
Zero order 
 
First order Hixon-Crowell 
 
Release 
mechanism 
r2 KH (mg
-h1/2) r2 n r2 K0 (% mg/h) r
2 K1 (h
-1) r2 Slope 
(n) 
F17 0.929 30.94 0.965 0.830 0.990 7.631 0.763 -0.096 0.887 -0.224 HIGUCHI 
F18 0.928 27.98 0.986 0.967 0.991 6.909 0.909 -0.059 0.949 -0.165 NFD 
F19 0.932 27.68 0.987 1.009 0.994 6.829 0.925 -0.056 0.958 -0.159 NFD 
F20 0.971 23.71 0.995 0.984 0.996 5.739 0.987 -0.04 0.995 -0.120 NFD 
F21 0.927 26.39 0.969 0.756 0.988 6.511 0.855 -0.062 0.920 -0.166 HIGUCHI 
F22 0.931 27.89 0.984 0.924 0.993 6.881 0.905 -0.061 0.948 -0.168 NFD 
F23 0.944 27.33 0.990 0.987 0.997 6.712 0.936 -0.054 0.967 -0.155 NFD 
F24 0.932 25.94 0.990 1.060 0.993 6.401 0.937 -0.048 0.963 -0.141 SUPER 
CASE II 
 
 
  
 
 
TABLE. 22 DETERMINATION OF ORDER OF RELEASE OF LORNOXICAM FROM NIOSOMAL FORMULATIONS 
      
 
Formulation 
 
 
Higuchi 
 
Korsemeyer-
Peppas 
 
Zero order 
 
First order 
 
Hixon-Crowell 
 
Release 
mechanism 
r2 KH (mg
-h1/2) r2 n r2 K0 (% mg/h) r
2 K1 (h
-1) r2 Slope 
(n) 
F25 0.939 29.17 0.991 0.943 0.995 7.175 0.887 -0.067 0.993 -0.082 NFD 
F26 0.939 29.13 0.991 1.008 0.995 7.167 0.920 -0.063 0.958 -0.175 SUPER 
CASE II 
F27 0.919 26.35 0.989 1.093 0.990 6.532 0.928 -0.050 0.956 -0.146 SUPER 
CASE II 
F28 0.958 24.81 0.996 0.979 0.998 6.052 0.970 -0.044 0.985 -0.131 NFD 
F29 0.948 28.39 0.980 0.847 0.997 6.959 0.928 -0.065 0.965 -0.176 NFD 
F30 0.884 23.72 0.954 0.908 0.973 5.944 0.894 -0.045 0.927 -0.133 NFD 
F31 0.941 24.39 0.978 0.882 0.996 5.997 0.950 -0.046 0.972 -0.134 NFD 
F32 0.909 22.49 0.973 1.006 0.985 5.595 0.937 -0.038 0.957 -0.117 SUPER 
CASE II 
 
 
             
 
 
 TABLE. 28 DETERMINATION OF ORDER OF RELEASE OF LORNOXICAM FROM NIOSOMALGEL 
FORMULATIONS 
 
 
Formulation 
 
 
Higuchi 
 
Korsemeyer-
Peppas 
 
Zero order 
 
First order 
 
Hixon-Crowell 
 
Release 
mechanism 
r2 KH (mg
-h1/2) r2 n r2 
K0 (% 
mg/h) 
r2 K1 (h
-1) r2 Slope (n) 
G1 0.9957 33.89 0.9863 1.347 0.9974 8.3158 0.8293 -0.0866 0.7491 0.362 HIGUCHI 
G2 0.9805 27.46 0.9719 2.1166 0.9925 6.7768 0.9377 -0.0438 0.8143 0.5254 HIGUCHI 
G3 0.9964 31.33 0.9835 1.462 0.9966 7.6827 0.9119 -0.0629 0.7293 0.4107 HIGUCHI 
 
 
 
 
 
 
TABLE. 23 COMPOSITION OF GEL 
SL. NO INGREDIENTS FOR 100 G 
1. Carbopol 940 1g 
2. Triethanolamine 0.165 ml 
3. Water To 100 ml 
4. Drug(Lornoxicam) 20 mg 
 
 
TABLE. 24 DRUG CONTENT OF GEL FORMULATION 
SL. NO FORMULATION DRUG CONTENT 
1. G1 95.4% 
2. G2 96.2% 
3 G3 95.0% 
 
 TABLE. 25 P
H
 VALUES 
S. No FG1 FG2 FG3 
1 6.8 6.8 6.8 
2 6.8 6.8 6.8 
3 6.8 6.8 6.8 
 
 
 
 
 
 
 
TABLE. 26 
BROOKFIELD DV II+LV VISCOMETER 
SPINDLE - 64 Temperatures: 28
◦ 
C 
S.NO             RPM 
 
VISCOSITY IN CPS 
 
 
FG2 
 
 
FG3 
1 0.1 20000 19500 
2 0.5 5210 3100 
3 1.0 3900 1510 
4 5.0 1180 670 
5 10.0 748 340 
6 20.0 500 200 
7 50.0 270 114 
8 100 175 72 
 
  
  
 
TABLE. 29 
% INHIBITION OF PAW OEDEMA 
S.NO GROUP TREATMENT ‘1’ h ‘2’ h ‘3’ h ‘4’ h ‘5’ h ‘6’ h 
 
‘24’ h   
1 Group –I FG1 28.40 28.64 32.58 33.90 35.08 41.76 
 
 
39.64 
2 Group –II FG2 11.0 12.59 13.74 14.96 18.51 19.54 
 
 
22.36 
 
 
3 Group-III 
FG3 
 
 
 
26.19 27.73 32.58 34.46 38.01 39.50 40.11 
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